PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"30922276","Optimal treatment of opioid induced constipation in daily clinical practice - an observational study","Neefjes ECW, van der Wijngaart H, van der Vorst MJDL, Ten Oever D, van der Vliet HJ, Beeker A, Rhodius CA, van den Berg HP, Berkhof J, Verheul HMW.","BMC Palliat Care. 2019 Mar 29;18(1):31. doi: 10.1186/s12904-019-0416-7.","Neefjes ECW","BMC Palliat Care","2019","2019/03/30","PMC6439982","","10.1186/s12904-019-0416-7"
"30277930","Identifying and Treating Opioid Side Effects: The Development of Methylnaltrexone","Moss J.","Anesthesiology. 2019 Jan;130(1):142-148. doi: 10.1097/ALN.0000000000002428.","Moss J","Anesthesiology","2019","2018/10/03","","","10.1097/ALN.0000000000002428"
"30189347","Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?","Pannemans J, Corsetti M.","Curr Opin Pharmacol. 2018 Dec;43:53-58. doi: 10.1016/j.coph.2018.08.008. Epub 2018 Sep 3.","Pannemans J","Curr Opin Pharmacol","2018","2018/09/07","","","10.1016/j.coph.2018.08.008"
"30020107","Methylnaltrexone-Associated Bowel Perforation in Postoperative Opioid-Induced Constipation and Ogilvie Syndrome: A Case Report","Blackney KA, Kamdar NV, Liu CA, Edwards DA.","A A Pract. 2019 Jan 15;12(2):44-46. doi: 10.1213/XAA.0000000000000840.","Blackney KA","A A Pract","2019","2018/07/19","","","10.1213/XAA.0000000000000840"
"30001114","Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators","Zheng Y, Obeng S, Wang H, Stevens DL, Komla E, Selley DE, Dewey WL, Akbarali HI, Zhang Y.","ACS Chem Neurosci. 2018 Dec 19;9(12):3028-3037. doi: 10.1021/acschemneuro.8b00234. Epub 2018 Jul 23.","Zheng Y","ACS Chem Neurosci","2018","2018/07/13","PMC6344324","NIHMS989182","10.1021/acschemneuro.8b00234"
"29979903","Methylnaltrexone bromide for the treatment of opioid-induced constipation","Mozaffari S, Nikfar S, Abdollahi M.","Expert Opin Pharmacother. 2018 Jul;19(10):1127-1135. doi: 10.1080/14656566.2018.1491549. Epub 2018 Jul 6.","Mozaffari S","Expert Opin Pharmacother","2018","2018/07/07","","","10.1080/14656566.2018.1491549"
"29869799","Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care","Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P.","Cochrane Database Syst Rev. 2018 Jun 5;6(6):CD006332. doi: 10.1002/14651858.CD006332.pub3.","Candy B","Cochrane Database Syst Rev","2018","2018/06/06","PMC6513061","","10.1002/14651858.CD006332.pub3"
"29621475","Management of Opioid-Induced Constipation in Patients with Malignancy","Garcia JM, Shamliyan TA.","Am J Med. 2018 Sep;131(9):1041-1051.e3. doi: 10.1016/j.amjmed.2018.02.038. Epub 2018 Apr 2.","Garcia JM","Am J Med","2018","2018/04/06","","","10.1016/j.amjmed.2018.02.038"
"29509554","Methylnaltrexone for Neostigmine-Resistant Ogilvie Syndrome","Tahir M, Singh A, Amjad W.","Am J Ther. 2018 Nov/Dec;25(6):e727-e728. doi: 10.1097/MJT.0000000000000743.","Tahir M","Am J Ther","2018","2018/03/07","","","10.1097/MJT.0000000000000743"
"29352328","Attenuation of serotonin-induced itch by sumatriptan: possible involvement of endogenous opioids","Haddadi NS, Foroutan A, Shakiba S, Afshari K, Ostadhadi S, Daneshpazhooh M, Dehpour AR.","Arch Dermatol Res. 2018 Mar;310(2):165-172. doi: 10.1007/s00403-018-1809-9. Epub 2018 Jan 19.","Haddadi NS","Arch Dermatol Res","2018","2018/01/21","","","10.1007/s00403-018-1809-9"
"29314653","Identification of oxymorphone as decomposition product of the permitted drug methylnaltrexone","Sobolevsky T, Kucherova Y, Ahrens B.","Drug Test Anal. 2018 May;10(5):892-895. doi: 10.1002/dta.2353. Epub 2018 Feb 6.","Sobolevsky T","Drug Test Anal","2018","2018/01/10","","","10.1002/dta.2353"
"29290404","The effects of recurrent hypoglycaemia and opioid antagonists on the adrenal catecholamine synthetic capacity in a rat model of HAAF","Senthilkumaran M, Bobrovskaya L.","Auton Neurosci. 2018 Mar;210:76-80. doi: 10.1016/j.autneu.2017.12.004. Epub 2017 Dec 16.","Senthilkumaran M","Auton Neurosci","2018","2018/01/02","","","10.1016/j.autneu.2017.12.004"
"29210822","PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS","Martinez-Cox S, Espinosa K, Friece C, Rahman A.","Gastroenterol Nurs. 2017 Nov/Dec;40(6):517-522. doi: 10.1097/SGA.0000000000000326.","Martinez-Cox S","Gastroenterol Nurs","2017","2017/12/07","","","10.1097/SGA.0000000000000326"
"29134730","Role of central versus peripheral opioid system in antinociceptive and anti-inflammatory effect of botulinum toxin type A in trigeminal region","Drinovac Vlah V, Filipović B, Bach-Rojecky L, Lacković Z.","Eur J Pain. 2018 Mar;22(3):583-591. doi: 10.1002/ejp.1146. Epub 2017 Nov 13.","Drinovac Vlah V","Eur J Pain","2018","2017/11/15","","","10.1002/ejp.1146"
"29092627","Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain","Murphy JA, Sheridan EA.","Ann Pharmacother. 2018 Apr;52(4):370-379. doi: 10.1177/1060028017739637. Epub 2017 Nov 2.","Murphy JA","Ann Pharmacother","2018","2017/11/03","","","10.1177/1060028017739637"
"28810695","Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial","Webster LR, Michna E, Khan A, Israel RJ, Harper JR.","Pain Med. 2017 Aug 1;18(8):1496-1504. doi: 10.1093/pm/pnx148.","Webster LR","Pain Med","2017","2017/08/17","PMC5914419","","10.1093/pm/pnx148"
"28776489","Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects","Zhang D, Ma JY, Yang M, Deng M, Liu H.","Xenobiotica. 2018 Aug;48(8):804-808. doi: 10.1080/00498254.2017.1364449. Epub 2017 Aug 17.","Zhang D","Xenobiotica","2018","2017/08/05","","","10.1080/00498254.2017.1364449"
"28580486","The Role of Endogenous Opioid System in the Regulation of Heart Tolerance to Stress-Induced Damage","Lishmanov YB, Tsibul'nikov SY, Naryzhnaya NV, Korobov MV, Maslov LN.","Bull Exp Biol Med. 2017 May;163(1):25-27. doi: 10.1007/s10517-017-3729-7. Epub 2017 Jun 3.","Lishmanov YB","Bull Exp Biol Med","2017","2017/06/06","","","10.1007/s10517-017-3729-7"
"28554659","Naloxegol, an opioid antagonist with reduced CNS penetration: Mode-of-action and human relevance for rat testicular tumours","Andersson H, Mitchard T, Johnson N, Floettmann E.","Toxicol Appl Pharmacol. 2017 Aug 15;329:85-95. doi: 10.1016/j.taap.2017.05.032. Epub 2017 May 26.","Andersson H","Toxicol Appl Pharmacol","2017","2017/05/31","","","10.1016/j.taap.2017.05.032"
"28363231","[Management of adverse effects of opioid therapy]","Wirz S.","Z Gastroenterol. 2017 Apr;55(4):394-400. doi: 10.1055/s-0043-103348. Epub 2017 Mar 31.","Wirz S","Z Gastroenterol","2017","2017/04/01","","","10.1055/s-0043-103348"
"28315644","Effects of Buprenorphine, Methylnaltrexone, and Their Combination on Gastrointestinal Transit in Healthy New Zealand White Rabbits","Martin-Flores M, Singh B, Walsh CA, Brooks EP, Taylor L, Mitchell LM.","J Am Assoc Lab Anim Sci. 2017 Mar 1;56(2):155-159.","Martin-Flores M","J Am Assoc Lab Anim Sci","2017","2017/03/20","PMC5361040","",""
"28168885","Methylnaltrexone Versus Naloxone for Opioid-Induced Constipation in the Medical Intensive Care Unit","Merchan C, Altshuler D, Papadopoulos J.","Ann Pharmacother. 2017 Mar;51(3):203-208. doi: 10.1177/1060028016677310. Epub 2016 Nov 13.","Merchan C","Ann Pharmacother","2017","2017/02/08","","","10.1177/1060028016677310"
"28110513","Effect of methylnaltrexone and naloxone on esophageal motor function in man","Scarpellini E, Pauwels A, Vos R, Rommel N, Tack J.","Neurogastroenterol Motil. 2017 Mar;29(3). doi: 10.1111/nmo.12938. Epub 2017 Jan 22.","Scarpellini E","Neurogastroenterol Motil","2017","2017/01/23","","","10.1111/nmo.12938"
"28092666","Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia","Corder G, Tawfik VL, Wang D, Sypek EI, Low SA, Dickinson JR, Sotoudeh C, Clark JD, Barres BA, Bohlen CJ, Scherrer G.","Nat Med. 2017 Feb;23(2):164-173. doi: 10.1038/nm.4262. Epub 2017 Jan 16.","Corder G","Nat Med","2017","2017/01/17","PMC5296291","NIHMS834527","10.1038/nm.4262"
"27860208","Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain","Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ.","Pain Pract. 2017 Jul;17(6):820-828. doi: 10.1111/papr.12535. Epub 2017 Feb 10.","Rauck R","Pain Pract","2017","2016/11/19","","","10.1111/papr.12535"
"27628064","Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study","Mori M, Ji Y, Kumar S, Ashikaga T, Ades S.","Int J Clin Oncol. 2017 Apr;22(2):397-404. doi: 10.1007/s10147-016-1041-6. Epub 2016 Sep 15.","Mori M","Int J Clin Oncol","2017","2016/09/16","","","10.1007/s10147-016-1041-6"
"27573565","Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer","Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J.","Ann Oncol. 2016 Nov;27(11):2032-2038. doi: 10.1093/annonc/mdw317. Epub 2016 Aug 29.","Janku F","Ann Oncol","2016","2016/08/31","PMC6267944","","10.1093/annonc/mdw317"
"27417446","Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced Constipation","Chokhavatia S, John ES, Bridgeman MB, Dixit D.","Drugs Aging. 2016 Aug;33(8):557-74. doi: 10.1007/s40266-016-0381-2.","Chokhavatia S","Drugs Aging","2016","2016/07/16","PMC5012150","","10.1007/s40266-016-0381-2"
"27412108","Protocol for a randomised control trial of methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients (MOTION)","Patel PB, Brett SJ, O'Callaghan D, Anjum A, Cross M, Warwick J, Gordon AC.","BMJ Open. 2016 Jul 13;6(7):e011750. doi: 10.1136/bmjopen-2016-011750.","Patel PB","BMJ Open","2016","2016/07/15","PMC4947806","","10.1136/bmjopen-2016-011750"
"26950234","Methylnaltrexone for the Treatment of Constipation in Critically Ill Children","López J, Fernández SN, Santiago MJ, Urbano J, González R, Fernández-Llamazares C, López-Herce J.","J Clin Gastroenterol. 2016 Apr;50(4):351-2. doi: 10.1097/MCG.0000000000000483.","López J","J Clin Gastroenterol","2016","2016/03/08","","","10.1097/MCG.0000000000000483"
"26839023","Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review","Mehta N, O'Connell K, Giambrone GP, Baqai A, Diwan S.","Postgrad Med. 2016;128(3):282-9. doi: 10.1080/00325481.2016.1149017. Epub 2016 Feb 23.","Mehta N","Postgrad Med","2016","2016/02/04","","","10.1080/00325481.2016.1149017"
"26702846","Opioid-induced constipation in chronic noncancer pain","Weber HC.","Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):11-7. doi: 10.1097/MED.0000000000000220.","Weber HC","Curr Opin Endocrinol Diabetes Obes","2016","2015/12/26","","","10.1097/MED.0000000000000220"
"26650429","Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis","Viscusi ER, Barrett AC, Paterson C, Forbes WP.","Reg Anesth Pain Med. 2016 Jan-Feb;41(1):93-8. doi: 10.1097/AAP.0000000000000341.","Viscusi ER","Reg Anesth Pain Med","2016","2015/12/10","PMC4684250","","10.1097/AAP.0000000000000341"
"26439728","Opioid-Induced Constipation Part 2: Newer Therapies #295","Badke A, Rosielle DA.","J Palliat Med. 2015 Oct;18(10):893-4. doi: 10.1089/jpm.2015.0153.","Badke A","J Palliat Med","2015","2015/10/07","","","10.1089/jpm.2015.0153"
"26360669","Constipation: opioid antagonists in people prescribed opioids","Ahmedzai SH, Boland JW.","BMJ Clin Evid. 2015 Sep 11;2015:2407.","Ahmedzai SH","BMJ Clin Evid","2015","2015/09/12","PMC4566814","",""
"26313157","Extended-release but not immediate-release and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-gut transit time in healthy subjects","Kolbow J, Modess C, Wegner D, Oswald S, Maritz MA, Rey H, Weitschies W, Siegmund W.","J Clin Pharmacol. 2016 Feb;56(2):239-45. doi: 10.1002/jcph.624. Epub 2015 Oct 20.","Kolbow J","J Clin Pharmacol","2016","2015/08/28","","","10.1002/jcph.624"
"26201215","Methylnaltrexone to Palliate Pruritus in Terminal Hepatic Disease","Hohl CM, Wong JK, Harlos MS.","J Palliat Care. 2015;31(2):124-6. doi: 10.1177/082585971503100209.","Hohl CM","J Palliat Care","2015","2015/07/24","","","10.1177/082585971503100209"
"26150678","Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation","Jones R, Prommer E, Backstedt D.","Am J Hosp Palliat Care. 2016 Nov;33(9):875-880. doi: 10.1177/1049909115593937. Epub 2015 Jul 6.","Jones R","Am J Hosp Palliat Care","2016","2015/07/08","","","10.1177/1049909115593937"
"26078009","Morphine Modulates Interleukin-4- or Breast Cancer Cell-induced Pro-metastatic Activation of Macrophages","Khabbazi S, Goumon Y, Parat MO.","Sci Rep. 2015 Jun 16;5:11389. doi: 10.1038/srep11389.","Khabbazi S","Sci Rep","2015","2015/06/17","PMC4468425","","10.1038/srep11389"
"26043235","The mu opioid receptor: A new target for cancer therapy?","Singleton PA, Moss J, Karp DD, Atkins JT, Janku F.","Cancer. 2015 Aug 15;121(16):2681-8. doi: 10.1002/cncr.29460. Epub 2015 Jun 4.","Singleton PA","Cancer","2015","2015/06/05","","","10.1002/cncr.29460"
"25973526","Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension","Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP.","J Palliat Med. 2015 Jul;18(7):593-600. doi: 10.1089/jpm.2014.0362. Epub 2015 May 14.","Bull J","J Palliat Med","2015","2015/05/15","PMC4492709","","10.1089/jpm.2014.0362"
"25967924","Laxatives for the management of constipation in people receiving palliative care","Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P.","Cochrane Database Syst Rev. 2015 May 13;2015(5):CD003448. doi: 10.1002/14651858.CD003448.pub4.","Candy B","Cochrane Database Syst Rev","2015","2015/05/14","PMC6956627","","10.1002/14651858.CD003448.pub4"
"25927665","Methylnaltrexone for Opioid-Induced Constipation in Children and Adolescents and Young Adults with Progressive Incurable Cancer at the End of Life","Flerlage JE, Baker JN.","J Palliat Med. 2015 Jul;18(7):631-3. doi: 10.1089/jpm.2014.0364. Epub 2015 Apr 30.","Flerlage JE","J Palliat Med","2015","2015/05/01","PMC4492591","","10.1089/jpm.2014.0364"
"25901587","Methylnaltrexone for opioid-induced constipation in patients at the end of life","Santucci G, Battista V.","Int J Palliat Nurs. 2015 Apr;21(4):162, 164. doi: 10.12968/ijpn.2015.21.4.162.","Santucci G","Int J Palliat Nurs","2015","2015/04/23","","","10.12968/ijpn.2015.21.4.162"
"25853862","Peripheral opioid antagonist enhances the effect of anti-tumor drug by blocking a cell growth-suppressive pathway in vivo","Suzuki M, Chiwaki F, Sawada Y, Ashikawa M, Aoyagi K, Fujita T, Yanagihara K, Komatsu M, Narita M, Suzuki T, Nagase H, Kushima R, Sakamoto H, Fukagawa T, Katai H, Nakagama H, Yoshida T, Uezono Y, Sasaki H.","PLoS One. 2015 Apr 8;10(4):e0123407. doi: 10.1371/journal.pone.0123407. eCollection 2015.","Suzuki M","PLoS One","2015","2015/04/09","PMC4390307","","10.1371/journal.pone.0123407"
"25810023","The effects of morphine and methylnaltrexone on gastrointestinal pain in healthy male participants","Brokjaer A, Olesen AE, Christrup LL, Dahan A, Drewes AM.","Neurogastroenterol Motil. 2015 May;27(5):693-704. doi: 10.1111/nmo.12545. Epub 2015 Mar 22.","Brokjaer A","Neurogastroenterol Motil","2015","2015/03/27","","","10.1111/nmo.12545"
"25567476","Methylnaltrexone to prevent intrathecal morphine-induced pruritus after Caesarean delivery: a multicentre, randomized clinical trial","Paech M, Sng B, Ng L, Nathan E, Sia A, Carvalho B.","Br J Anaesth. 2015 Mar;114(3):469-76. doi: 10.1093/bja/aeu410. Epub 2015 Jan 7.","Paech M","Br J Anaesth","2015","2015/01/09","","","10.1093/bja/aeu410"
"25460532","Narcotic-induced pain","Thapa SD, Schairer J.","Am J Med. 2015 Apr;128(4):e7-8. doi: 10.1016/j.amjmed.2014.10.044. Epub 2014 Nov 22.","Thapa SD","Am J Med","2015","2014/12/03","","","10.1016/j.amjmed.2014.10.044"
"25147168","Off-label uses of alvimopan and methylnaltrexone","Rodriguez RW.","Am J Health Syst Pharm. 2014 Sep 1;71(17):1450-5. doi: 10.2146/ajhp130632.","Rodriguez RW","Am J Health Syst Pharm","2014","2014/08/23","","","10.2146/ajhp130632"
"25046272","Peripheral opioid receptor blockade increases postoperative morphine demands--a randomized, double-blind, placebo-controlled trial","Jagla C, Martus P, Stein C.","Pain. 2014 Oct;155(10):2056-62. doi: 10.1016/j.pain.2014.07.011. Epub 2014 Jul 18.","Jagla C","Pain","2014","2014/07/22","","","10.1016/j.pain.2014.07.011"
"24973366","GI relief may come sooner than later for patients with chronic noncancer pain","Thompson CA.","Am J Health Syst Pharm. 2014 Jul 15;71(14):1153-5. doi: 10.2146/news140049.","Thompson CA","Am J Health Syst Pharm","2014","2014/06/29","","","10.2146/news140049"
"24871705","Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers","Zacny JP, Wroblewski K, Coalson DW.","Psychopharmacology (Berl). 2015 Jan;232(1):63-73. doi: 10.1007/s00213-014-3637-8. Epub 2014 May 29.","Zacny JP","Psychopharmacology (Berl)","2015","2014/05/30","PMC4295206","NIHMS599937","10.1007/s00213-014-3637-8"
"24815199","Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials","Nalamachu SR, Pergolizzi J, Taylor R Jr, Slatkin NE, Barrett AC, Yu J, Bortey E, Paterson C, Forbes WP.","Pain Pract. 2015 Jul;15(6):564-71. doi: 10.1111/papr.12218. Epub 2014 May 10.","Nalamachu SR","Pain Pract","2015","2014/05/13","","","10.1111/papr.12218"
"24644335","Paediatric palliative care: intravenous methylnaltrexone relieves constipation","Yeomanson D, Chohan O, Mayer A.","BMJ Support Palliat Care. 2013 Mar;3(1):103-5. doi: 10.1136/bmjspcare-2012-000291. Epub 2012 Nov 2.","Yeomanson D","BMJ Support Palliat Care","2013","2014/03/20","","","10.1136/bmjspcare-2012-000291"
"24644334","Uptake of methylnaltrexone in Australian patients with opioid-induced constipation: a review of the number of prescriptions presented in the first 12 months of subsidisation","Clark K, Rowett D, Robinson M, Currow DC.","BMJ Support Palliat Care. 2013 Mar;3(1):98-102. doi: 10.1136/bmjspcare-2012-000284. Epub 2012 Nov 15.","Clark K","BMJ Support Palliat Care","2013","2014/03/20","","","10.1136/bmjspcare-2012-000284"
"24571193","The effect of methylnaltrexone on the side effects of intrathecal morphine after orthopedic surgery under spinal anesthesia","Zand F, Amini A, Asadi S, Farbood A.","Pain Pract. 2015 Apr;15(4):348-54. doi: 10.1111/papr.12185. Epub 2014 Feb 27.","Zand F","Pain Pract","2015","2014/02/28","","","10.1111/papr.12185"
"24512968","Opioid antagonists","Barnett V, Twycross R, Mihalyo M, Wilcock A.","J Pain Symptom Manage. 2014 Feb;47(2):341-52. doi: 10.1016/j.jpainsymman.2013.12.223.","Barnett V","J Pain Symptom Manage","2014","2014/02/12","","","10.1016/j.jpainsymman.2013.12.223"
"24358569","Giving laxatives safely and effectively","Daniels G, Daniels G.","Medsurg Nurs. 2013 Sep-Oct;22(5):290-6, 302.","Daniels G","Medsurg Nurs","2013","2013/12/24","","",""
"24244983","The role of methylnaltrexone in opioid-induced constipation","Hellwig TR, Pottebaum AA.","S D Med. 2013 Oct;66(10):425, 427.","Hellwig TR","S D Med","2013","2013/11/20","","",""
"24132534","[Opiate induced constipation--mechanisms, relevance and treatment]","Müller-Lissner S.","Dtsch Med Wochenschr. 2013 Oct;138(43):2207-11. doi: 10.1055/s-0033-1349447. Epub 2013 Oct 16.","Müller-Lissner S","Dtsch Med Wochenschr","2013","2013/10/18","","","10.1055/s-0033-1349447"
"23984635","Unexpected side effect of methylnaltrexone","Stettler A, Zulian GB.","J Palliat Med. 2013 Oct;16(10):1168. doi: 10.1089/jpm.2013.0264. Epub 2013 Aug 28.","Stettler A","J Palliat Med","2013","2013/08/30","","","10.1089/jpm.2013.0264"
"23881667","Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone","Rauck RL.","Drugs. 2013 Aug;73(12):1297-306. doi: 10.1007/s40265-013-0084-5.","Rauck RL","Drugs","2013","2013/07/25","","","10.1007/s40265-013-0084-5"
"23877147","Use of methylnaltrexone to induce laxation in acutely injured patients with burns and necrotizing soft-tissue infections","Hewitt K, Lin H, Faraklas I, Morris S, Cochran A, Saffle J.","J Burn Care Res. 2014 Mar-Apr;35(2):e106-11. doi: 10.1097/BCR.0b013e31829b399d.","Hewitt K","J Burn Care Res","2014","2013/07/24","","","10.1097/BCR.0b013e31829b399d"
"23834367","Pharmacologic treatment of opioid-induced constipation","Wang CZ, Yuan CS.","Expert Opin Investig Drugs. 2013 Oct;22(10):1225-7. doi: 10.1517/13543784.2013.819341. Epub 2013 Jul 9.","Wang CZ","Expert Opin Investig Drugs","2013","2013/07/10","","","10.1517/13543784.2013.819341"
"23802360","[Constipation management in palliative care]","Lötscher C, Ivanovi N, Fringer A.","Krankenpfl Soins Infirm. 2013;106(6):32-3.","Lötscher C","Krankenpfl Soins Infirm","2013","2013/06/28","","",""
"23782897","Overview and treatment of opioid-induced constipation","McCarberg BH.","Postgrad Med. 2013 Jul;125(4):7-17. doi: 10.3810/pgm.2013.07.2651. Epub 2013 Jun 19.","McCarberg BH","Postgrad Med","2013","2013/06/21","","","10.3810/pgm.2013.07.2651"
"23766091","Methylnaltrexone for opioid-induced constipation in pediatric oncology patients","Rodrigues A, Wong C, Mattiussi A, Alexander S, Lau E, Dupuis LL.","Pediatr Blood Cancer. 2013 Oct;60(10):1667-70. doi: 10.1002/pbc.24615. Epub 2013 Jun 14.","Rodrigues A","Pediatr Blood Cancer","2013","2013/06/15","","","10.1002/pbc.24615"
"23752879","Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis","Ford AC, Brenner DM, Schoenfeld PS.","Am J Gastroenterol. 2013 Oct;108(10):1566-74; quiz 1575. doi: 10.1038/ajg.2013.169. Epub 2013 Jun 11.","Ford AC","Am J Gastroenterol","2013","2013/06/12","","","10.1038/ajg.2013.169"
"23746197","Methylnaltrexone use in a seventeen-month-old female with progressive cancer and rectal prolapse","Laubisch JE, Baker JN.","J Palliat Med. 2013 Nov;16(11):1486-8. doi: 10.1089/jpm.2012.0600. Epub 2013 Jun 7.","Laubisch JE","J Palliat Med","2013","2013/06/11","PMC3822361","","10.1089/jpm.2012.0600"
"23713743","Effects of remifentanil on the esophagogastric junction and swallowing","Savilampi J, Ahlstrand R, Magnuson A, Wattwil M.","Acta Anaesthesiol Scand. 2013 Sep;57(8):1002-9. doi: 10.1111/aas.12134. Epub 2013 May 29.","Savilampi J","Acta Anaesthesiol Scand","2013","2013/05/30","","","10.1111/aas.12134"
"23549670","The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist","Tsuruda PR, Vickery RG, Long DD, Armstrong SR, Beattie DT.","Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91. doi: 10.1007/s00210-013-0850-7. Epub 2013 Apr 4.","Tsuruda PR","Naunyn Schmiedebergs Arch Pharmacol","2013","2013/04/04","","","10.1007/s00210-013-0850-7"
"23478431","Pharmacological treatment of constipation in palliative care","Clemens KE, Faust M, Jaspers B, Mikus G.","Curr Opin Support Palliat Care. 2013 Jun;7(2):183-91. doi: 10.1097/SPC.0b013e32835f1e17.","Clemens KE","Curr Opin Support Palliat Care","2013","2013/03/13","","","10.1097/SPC.0b013e32835f1e17"
"23391399","Opiate receptor antagonists for treatment of severe pruritus associated with advanced cholestatic liver disease","Kumar N, Garg N, Bailey A.","J Palliat Med. 2013 Feb;16(2):122-3. doi: 10.1089/jpm.2012.0452.","Kumar N","J Palliat Med","2013","2013/02/09","","","10.1089/jpm.2012.0452"
"23372103","Laxatives or methylnaltrexone for the management of constipation in palliative care patients","Brick N.","Clin J Oncol Nurs. 2013 Feb;17(1):91-2. doi: 10.1188/13.CJON.91-92.","Brick N","Clin J Oncol Nurs","2013","2013/02/02","","","10.1188/13.CJON.91-92"
"23361094","Effects of methylnaltrexone on guinea pig gastrointestinal motility","Anselmi L, Huynh J, Vegezzi G, Sternini C.","Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr;386(4):279-86. doi: 10.1007/s00210-013-0833-8. Epub 2013 Jan 30.","Anselmi L","Naunyn Schmiedebergs Arch Pharmacol","2013","2013/01/31","PMC3657610","NIHMS440369","10.1007/s00210-013-0833-8"
"23334174","Gastrointestinal dysmotility: evidence and clinical management","Chapman MJ, Nguyen NQ, Deane AM.","Curr Opin Clin Nutr Metab Care. 2013 Mar;16(2):209-16. doi: 10.1097/MCO.0b013e32835c1fa5.","Chapman MJ","Curr Opin Clin Nutr Metab Care","2013","2013/01/22","","","10.1097/MCO.0b013e32835c1fa5"
"23327357","Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation","Lin DH, Wang CZ, Qin LF, Xie XX, Wang JT, Gu M, McEntee E, Yuan CS.","Drug Dev Ind Pharm. 2014 Feb;40(2):186-91. doi: 10.3109/03639045.2012.753899. Epub 2013 Jan 18.","Lin DH","Drug Dev Ind Pharm","2014","2013/01/19","","","10.3109/03639045.2012.753899"
"23207598","Motility disorders of the colon and rectum","Gras B, Magge S, Bloom A, Lembo A.","Curr Opin Gastroenterol. 2013 Jan;29(1):66-71. doi: 10.1097/MOG.0b013e32835a80e7.","Gras B","Curr Opin Gastroenterol","2013","2012/12/05","","","10.1097/MOG.0b013e32835a80e7"
"23135875","WYE-120318, a ring contraction product of methylnaltrexone, and structure revision of coniothyrione","Kong F, Zhu T, Pan W, Tsao R, Pagano TG, Nguyen B, Marquez B.","Magn Reson Chem. 2012 Dec;50(12):829-33. doi: 10.1002/mrc.3892. Epub 2012 Nov 8.","Kong F","Magn Reson Chem","2012","2012/11/09","","","10.1002/mrc.3892"
"23121581","Subsidised use of methylnaltrexone in Australia for palliative care","Rowett DS, Clark K, Robinson MK, Currow DC.","Med J Aust. 2012 Nov 5;197(9):492. doi: 10.5694/mja12.11398.","Rowett DS","Med J Aust","2012","2012/11/06","","","10.5694/mja12.11398"
"22946581","An unusual case of Ogilvie syndrome in a pediatric oncology patient receiving palliative care after failed treatment with neostigmine","Johnson LM, Spraker HL, Coleman JL, Baker JN.","J Palliat Med. 2012 Sep;15(9):1042-6. doi: 10.1089/jpm.2011.0450.","Johnson LM","J Palliat Med","2012","2012/09/06","","","10.1089/jpm.2011.0450"
"22770490","Methylnaltrexone for opioid-induced constipation in a pediatric oncology patient","Kissling KT, Mohassel LR, Heintz J.","J Pain Symptom Manage. 2012 Jul;44(1):e1-3. doi: 10.1016/j.jpainsymman.2012.04.001.","Kissling KT","J Pain Symptom Manage","2012","2012/07/10","","","10.1016/j.jpainsymman.2012.04.001"
"22747544","Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal?","Holzer P.","Curr Pharm Des. 2012;18(37):6010-20. doi: 10.2174/138161212803582388.","Holzer P","Curr Pharm Des","2012","2012/07/04","","","10.2174/138161212803582388"
"22413747","Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone","Gatti A, Sabato AF.","Clin Drug Investig. 2012 May 1;32(5):293-301. doi: 10.2165/11598000-000000000-00000.","Gatti A","Clin Drug Investig","2012","2012/03/15","","","10.2165/11598000-000000000-00000"
"22386181","Use of methylnaltrexone for the treatment of opioid-induced constipation in critical care patients","Sawh SB, Selvaraj IP, Danga A, Cotton AL, Moss J, Patel PB.","Mayo Clin Proc. 2012 Mar;87(3):255-9. doi: 10.1016/j.mayocp.2011.11.014.","Sawh SB","Mayo Clin Proc","2012","2012/03/06","PMC3498420","","10.1016/j.mayocp.2011.11.014"
"22385598","Management of postoperative ileus","Thompson M, Magnuson B.","Orthopedics. 2012 Mar;35(3):213-7. doi: 10.3928/01477447-20120222-08.","Thompson M","Orthopedics","2012","2012/03/06","","","10.3928/01477447-20120222-08"
"22289023","Effects of methylnaltrexone in patients with narcotic bowel syndrome: a pilot observational study","Gibson PR, Morrison G.","Intern Med J. 2012 Aug;42(8):907-12. doi: 10.1111/j.1445-5994.2012.02726.x.","Gibson PR","Intern Med J","2012","2012/02/01","","","10.1111/j.1445-5994.2012.02726.x"
"22234164","Alternatives to prokinetics to move the pylorus and colon","Pfab F, Nowak-Machen M, Napadow V, Fleckenstein J.","Curr Opin Clin Nutr Metab Care. 2012 Mar;15(2):166-73. doi: 10.1097/MCO.0b013e32834f3000.","Pfab F","Curr Opin Clin Nutr Metab Care","2012","2012/01/12","","","10.1097/MCO.0b013e32834f3000"
"22150655","Management of constipation in patients receiving palliative care","Cayley WE Jr.","Am Fam Physician. 2011 Dec 1;84(11):1227-8.","Cayley WE Jr","Am Fam Physician","2011","2011/12/14","","",""
"22045373","Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials","Slatkin NE, Lynn R, Su C, Wang W, Israel RJ.","J Pain Symptom Manage. 2011 Nov;42(5):754-60. doi: 10.1016/j.jpainsymman.2011.02.015.","Slatkin NE","J Pain Symptom Manage","2011","2011/11/03","","","10.1016/j.jpainsymman.2011.02.015"
"22034654","Reversal of morphine-induced urinary retention after methylnaltrexone","Garten L, Bührer C.","Arch Dis Child Fetal Neonatal Ed. 2012 Mar;97(2):F151-3. doi: 10.1136/archdischild-2011-300213. Epub 2011 Oct 27.","Garten L","Arch Dis Child Fetal Neonatal Ed","2012","2011/10/29","","","10.1136/archdischild-2011-300213"
"21998076","Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery","Anissian L, Schwartz HW, Vincent K, Vincent HK, Carpenito J, Stambler N, Ramakrishna T.","J Hosp Med. 2012 Feb;7(2):67-72. doi: 10.1002/jhm.943. Epub 2011 Oct 13.","Anissian L","J Hosp Med","2012","2011/10/15","","","10.1002/jhm.943"
"21997147","Arresting the development of morphine tolerance and dependence","Hales TG.","Br J Anaesth. 2011 Nov;107(5):653-5. doi: 10.1093/bja/aer294.","Hales TG","Br J Anaesth","2011","2011/10/15","","","10.1093/bja/aer294"
"21992933","Methylnaltrexone for treatment of acute colonic pseudo-obstruction","Weinstock LB, Chang AC.","J Clin Gastroenterol. 2011 Nov-Dec;45(10):883-4. doi: 10.1097/MCG.0b013e31821100ab.","Weinstock LB","J Clin Gastroenterol","2011","2011/10/14","","","10.1097/MCG.0b013e31821100ab"
"21880450","Quantitative determination of methylnaltrexone in human serum using liquid chromatography-tandem mass spectrometry","Oswald S, Schumacher G, Siegmund W.","J Pharm Biomed Anal. 2011 Dec 15;56(5):1079-84. doi: 10.1016/j.jpba.2011.08.016. Epub 2011 Aug 12.","Oswald S","J Pharm Biomed Anal","2011","2011/09/02","","","10.1016/j.jpba.2011.08.016"
"21876436","Methylnaltrexone in treatment of opioid-induced constipation in a pediatric patient","Lee JM, Mooney J.","Clin J Pain. 2012 May;28(4):338-41. doi: 10.1097/AJP.0b013e31822ad94c.","Lee JM","Clin J Pain","2012","2011/08/31","","","10.1097/AJP.0b013e31822ad94c"
"21823547","Current concepts in the management of opioid-induced constipation: a perfect review with an imperfect concept","Ruan X.","J Opioid Manag. 2011 May-Jun;7(3):167, 170; author reply 170-2. doi: 10.5055/jom.2011.0059.","Ruan X","J Opioid Manag","2011","2011/08/10","","","10.5055/jom.2011.0059"
"21810165","Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis","Michna E, Weil AJ, Duerden M, Schulman S, Wang W, Tzanis E, Zhang H, Yu D, Manley A, Randazzo B.","Pain Med. 2011 Aug;12(8):1223-30. doi: 10.1111/j.1526-4637.2011.01189.x. Epub 2011 Aug 2.","Michna E","Pain Med","2011","2011/08/04","","","10.1111/j.1526-4637.2011.01189.x"
"21785031","Use of pure opioid antagonists for management of opioid-induced pruritus","Miller JL, Hagemann TM.","Am J Health Syst Pharm. 2011 Aug 1;68(15):1419-25. doi: 10.2146/ajhp100475.","Miller JL","Am J Health Syst Pharm","2011","2011/07/26","","","10.2146/ajhp100475"
"21657861","Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study","Lipman AG, Karver S, Cooney GA, Stambler N, Israel RJ.","J Pain Palliat Care Pharmacother. 2011;25(2):136-45. doi: 10.3109/15360288.2011.573531.","Lipman AG","J Pain Palliat Care Pharmacother","2011","2011/06/11","","","10.3109/15360288.2011.573531"
"21606123","Treating constipation in palliative care: the impact of other factors aside from opioids","Clark K, Byfieldt N, Dawe M, Currow DC.","Am J Hosp Palliat Care. 2012 Mar;29(2):122-5. doi: 10.1177/1049909111409389. Epub 2011 May 23.","Clark K","Am J Hosp Palliat Care","2012","2011/05/25","","","10.1177/1049909111409389"
"21471758","Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials","Yu CS, Chun HK, Stambler N, Carpenito J, Schulman S, Tzanis E, Randazzo B.","Dis Colon Rectum. 2011 May;54(5):570-8. doi: 10.1007/DCR.0b013e3182092bde.","Yu CS","Dis Colon Rectum","2011","2011/04/08","","","10.1007/DCR.0b013e3182092bde"
"21454318","Methylnaltrexone: treatment for opioid-induced constipation--not convinced yet","HaiNan Liu, Xiulu Ruan.","Am J Hosp Palliat Care. 2011 Jun;28(4):290; author reply 291. doi: 10.1177/1049909111402817. Epub 2011 Mar 30.","HaiNan Liu","Am J Hosp Palliat Care","2011","2011/04/02","","","10.1177/1049909111402817"
"21429809","Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study","Michna E, Blonsky ER, Schulman S, Tzanis E, Manley A, Zhang H, Iyer S, Randazzo B.","J Pain. 2011 May;12(5):554-62. doi: 10.1016/j.jpain.2010.11.008. Epub 2011 Mar 22.","Michna E","J Pain","2011","2011/03/25","","","10.1016/j.jpain.2010.11.008"
"21376180","Resolution of opioid-induced postoperative ileus in a newborn infant after methylnaltrexone","Garten L, Degenhardt P, Bührer C.","J Pediatr Surg. 2011 Mar;46(3):e13-5. doi: 10.1016/j.jpedsurg.2010.10.015.","Garten L","J Pediatr Surg","2011","2011/03/08","","","10.1016/j.jpedsurg.2010.10.015"
"21249653","Laxatives or methylnaltrexone for the management of constipation in palliative care patients","Candy B, Jones L, Goodman ML, Drake R, Tookman A.","Cochrane Database Syst Rev. 2011 Jan 19;(1):CD003448. doi: 10.1002/14651858.CD003448.pub3.","Candy B","Cochrane Database Syst Rev","2011","2011/01/21","","","10.1002/14651858.CD003448.pub3"
"21222554","Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration","Rotshteyn Y, Boyd TA, Yuan CS.","Expert Opin Drug Metab Toxicol. 2011 Feb;7(2):227-35. doi: 10.1517/17425255.2011.549824. Epub 2011 Jan 11.","Rotshteyn Y","Expert Opin Drug Metab Toxicol","2011","2011/01/13","","","10.1517/17425255.2011.549824"
"21211500","Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms","Iyer SS, Randazzo BP, Tzanis EL, Schulman SL, Zhang H, Wang W, Manley AL.","Value Health. 2011 Jan;14(1):177-83. doi: 10.1016/j.jval.2010.11.003.","Iyer SS","Value Health","2011","2011/01/08","","","10.1016/j.jval.2010.11.003"
"21198709","Endogenously released opioids mediate meal-induced gastric relaxation via peripheral mu-opioid receptors","Janssen P, Pottel H, Vos R, Tack J.","Aliment Pharmacol Ther. 2011 Mar;33(5):607-14. doi: 10.1111/j.1365-2036.2010.04557.x. Epub 2010 Dec 29.","Janssen P","Aliment Pharmacol Ther","2011","2011/01/05","","","10.1111/j.1365-2036.2010.04557.x"
"20839388","The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health","Wong BS, Rao AS, Camilleri M, Manabe N, McKinzie S, Busciglio I, Burton DD, Ryks M, Zinsmeister AR.","Aliment Pharmacol Ther. 2010 Oct;32(7):884-93. doi: 10.1111/j.1365-2036.2010.04422.x.","Wong BS","Aliment Pharmacol Ther","2010","2010/09/15","","","10.1111/j.1365-2036.2010.04422.x"
"20832981","Methylnaltrexone in the treatment of opioid-induced constipation in cancer patients receiving palliative care: willingness-to-pay and cost-benefit analysis","Iskedjian M, Iyer S, Librach SL, Wang M, Farah B, Berbari J.","J Pain Symptom Manage. 2011 Jan;41(1):104-15. doi: 10.1016/j.jpainsymman.2010.04.012. Epub 2010 Sep 15.","Iskedjian M","J Pain Symptom Manage","2011","2010/09/14","","","10.1016/j.jpainsymman.2010.04.012"
"20801917","Methylnaltrexone: treatment for opioid-induced constipation","Licup N, Baumrucker SJ.","Am J Hosp Palliat Care. 2011 Feb;28(1):59-61. doi: 10.1177/1049909110373507. Epub 2010 Aug 27.","Licup N","Am J Hosp Palliat Care","2011","2010/08/31","","","10.1177/1049909110373507"
"20799006","The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review","Leppert W.","Adv Ther. 2010 Oct;27(10):714-30. doi: 10.1007/s12325-010-0063-0. Epub 2010 Aug 26.","Leppert W","Adv Ther","2010","2010/08/28","","","10.1007/s12325-010-0063-0"
"20619194","Methylnaltrexone and gastrointestinal perforation","Mackey AC, Green L, Greene P, Avigan M.","J Pain Symptom Manage. 2010 Jul;40(1):e1-3. doi: 10.1016/j.jpainsymman.2010.01.011.","Mackey AC","J Pain Symptom Manage","2010","2010/07/13","","","10.1016/j.jpainsymman.2010.01.011"
"20426500","Methylnaltrexone","Garnock-Jones KP, McKeage K.","Drugs. 2010 May 7;70(7):919-28. doi: 10.2165/11204520-000000000-00000.","Garnock-Jones KP","Drugs","2010","2010/04/30","","","10.2165/11204520-000000000-00000"
"20345211","Emerging new therapeutic options for the management of opioid induced constipation","Kapoor S.","J Pain Palliat Care Pharmacother. 2010 Mar;24(1):98-9. doi: 10.3109/15360280903475593.","Kapoor S","J Pain Palliat Care Pharmacother","2010","2010/03/30","","","10.3109/15360280903475593"
"20173089","In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone","Tong Z, Chandrasekaran A, Li H, Rotshteyn Y, Erve JC, Demaio W, Talaat R, Hultin T, Scatina J.","Drug Metab Dispos. 2010 May;38(5):801-7. doi: 10.1124/dmd.110.032169. Epub 2010 Feb 19.","Tong Z","Drug Metab Dispos","2010","2010/02/23","","","10.1124/dmd.110.032169"
"20134275","Subcutaneous methylnaltrexone to restore postoperative bowel function in a long-term opiate user","Ladanyi A, Temkin SM, Moss J.","Int J Gynecol Cancer. 2010 Feb;20(2):308-10. doi: 10.1111/IGC.0b013e3181cd1828.","Ladanyi A","Int J Gynecol Cancer","2010","2010/02/06","","","10.1111/IGC.0b013e3181cd1828"
"20096019","Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis","Earnshaw SR, Klok RM, Iyer S, McDade C.","Aliment Pharmacol Ther. 2010 Apr;31(8):911-21. doi: 10.1111/j.1365-2036.2010.04244.x. Epub 2010 Jan 20.","Earnshaw SR","Aliment Pharmacol Ther","2010","2010/01/26","","","10.1111/j.1365-2036.2010.04244.x"
"20081727","Methylnaltrexone: a subcutaneous treatment for opioid-induced constipation in palliative care patients","Kyle G.","Int J Palliat Nurs. 2009 Nov;15(11):533-40. doi: 10.12968/ijpn.2009.15.11.45492.","Kyle G","Int J Palliat Nurs","2009","2010/01/19","","","10.12968/ijpn.2009.15.11.45492"
"20073411","Methylnaltrexone potentiates body weight and fat reduction with leptin","Yuan CS, Sun S, Attele A, Wang CZ, Tong R, Israel RJ.","J Opioid Manag. 2009 Nov-Dec;5(6):373-8. doi: 10.5055/jom.2009.0037.","Yuan CS","J Opioid Manag","2009","2010/01/16","","","10.5055/jom.2009.0037"
"20053817","Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans","Chandrasekaran A, Tong Z, Li H, Erve JC, DeMaio W, Goljer I, McConnell O, Rotshteyn Y, Hultin T, Talaat R, Scatina J.","Drug Metab Dispos. 2010 Apr;38(4):606-16. doi: 10.1124/dmd.109.031179. Epub 2010 Jan 6.","Chandrasekaran A","Drug Metab Dispos","2010","2010/01/08","","","10.1124/dmd.109.031179"
"19898269","Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction","Baker DE.","Rev Gastroenterol Disord. 2009 Summer;9(3):E84-93.","Baker DE","Rev Gastroenterol Disord","2009","2009/11/10","","",""
"19831162","Long-term use of methylnaltrexone for the management of constipation in advanced cancer","Dutka J, Lowe SS, Michaud M, Watanabe S.","J Support Oncol. 2009 Sep-Oct;7(5):177-9.","Dutka J","J Support Oncol","2009","2009/10/17","","",""
"19817669","Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness","Diego L, Atayee R, Helmons P, von Gunten CF.","Expert Rev Gastroenterol Hepatol. 2009 Oct;3(5):473-85. doi: 10.1586/egh.09.42.","Diego L","Expert Rev Gastroenterol Hepatol","2009","2009/10/13","","","10.1586/egh.09.42"
"19773693","Effectiveness of two opioid antagonists in treating opioid-induced constipation","Healy R.","Br J Nurs. 2009 Sep 10-23;18(16):998-1002. doi: 10.12968/bjon.2009.18.16.43969.","Healy R","Br J Nurs","2009","2009/09/24","","","10.12968/bjon.2009.18.16.43969"
"19743572","Methylnaltrexone: new drug. Opiate-induced constipation: barely more effective than placebo","","Prescrire Int. 2009 Aug;18(102):158.","","Prescrire Int","2009","2009/09/12","","",""
"19736901","Methylnaltrexone reduced body weight gain in ob/ob mice","Yuan CS, Wang CZ, Attele A, Zhang L.","J Opioid Manag. 2009 Jul-Aug;5(4):213-8. doi: 10.5055/jom.2009.0023.","Yuan CS","J Opioid Manag","2009","2009/09/10","","","10.5055/jom.2009.0023"
"19713070","Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness","Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, Israel RJ.","J Pain Symptom Manage. 2009 Nov;38(5):683-90. doi: 10.1016/j.jpainsymman.2009.02.234. Epub 2009 Aug 26.","Chamberlain BH","J Pain Symptom Manage","2009","2009/08/29","","","10.1016/j.jpainsymman.2009.02.234"
"19690895","[Methylnaltrexone. A new approach for therapy of opioid-induced obstipation]","Chappell D, Conzen P.","Schmerz. 2009 Oct;23(5):471-8. doi: 10.1007/s00482-009-0824-3.","Chappell D","Schmerz","2009","2009/08/20","","","10.1007/s00482-009-0824-3"
"19661297","Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells","Wang CZ, Li XL, Sun S, Xie JT, Aung HH, Tong R, McEntee E, Yuan CS.","Anticancer Res. 2009 Aug;29(8):2927-32.","Wang CZ","Anticancer Res","2009","2009/08/08","","",""
"19605844","Methylnaltrexone","Hendrikx JJ, Beijnen JH, Schellens JH.","Oncologist. 2009 Jul;14(7):679-82. doi: 10.1634/theoncologist.2009-0049. Epub 2009 Jul 15.","Hendrikx JJ","Oncologist","2009","2009/07/17","","","10.1634/theoncologist.2009-0049"
"19585156","[Successful treatment of treatment-resistant opioid-induced constipation in a patient with incomplete paraplegia with methylnaltrexone]","Lux EA.","Schmerz. 2009 Oct;23(5):523-4. doi: 10.1007/s00482-009-0820-7.","Lux EA","Schmerz","2009","2009/07/09","","","10.1007/s00482-009-0820-7"
"19583062","Preventing paralytic ileus: can the anesthesiologist help","Frost EA.","Middle East J Anaesthesiol. 2009 Jun;20(2):159-65.","Frost EA","Middle East J Anaesthesiol","2009","2009/07/09","","",""
"19555139","New drug update: 2008","Hussar DA.","Consult Pharm. 2009 Apr;24(4):268-70, 273-80. doi: 10.4140/tcp.n.2009.268.","Hussar DA","Consult Pharm","2009","2009/06/27","","","10.4140/tcp.n.2009.268"
"19555136","Methylnaltrexone methobromide: the first peripherally active, centrally inactive opioid receptor-antagonist","Guay DR.","Consult Pharm. 2009 Mar;24(3):210-26. doi: 10.4140/tcp.n.2009.210.","Guay DR","Consult Pharm","2009","2009/06/27","","","10.4140/tcp.n.2009.210"
"19531698","An overview of constipation and newer therapies","Enck RE.","Am J Hosp Palliat Care. 2009 Jun-Jul;26(3):157-8. doi: 10.1177/1049909109337298.","Enck RE","Am J Hosp Palliat Care","2009","2009/06/18","","","10.1177/1049909109337298"
"19399212","Pharmacological management of postoperative ileus","Zeinali F, Stulberg JJ, Delaney CP.","Can J Surg. 2009 Apr;52(2):153-7.","Zeinali F","Can J Surg","2009","2009/04/29","PMC2663489","",""
"19382412","The role of peripheral opiate antagonists in pain medicine and perioperative care","Tanaka PP, Moss J.","Rev Bras Anestesiol. 2008 Sep-Oct;58(5):540-7, 533-9. doi: 10.1590/s0034-70942008000500011.","Tanaka PP","Rev Bras Anestesiol","2008","2009/04/23","","","10.1590/s0034-70942008000500011"
"19364251","Methylnaltrexone: the answer to opioid-induced constipation?","Cannom RR, Mason RJ.","Expert Opin Pharmacother. 2009 Apr;10(6):1039-45. doi: 10.1517/14656560902833914.","Cannom RR","Expert Opin Pharmacother","2009","2009/04/15","","","10.1517/14656560902833914"
"19345246","Opioid receptors in the gastrointestinal tract","Holzer P.","Regul Pept. 2009 Jun 5;155(1-3):11-7. doi: 10.1016/j.regpep.2009.03.012. Epub 2009 Apr 2.","Holzer P","Regul Pept","2009","2009/04/07","PMC3163293","UKMS32582","10.1016/j.regpep.2009.03.012"
"19322519","Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma","Kast RE.","J Neurooncol. 2009 Sep;94(2):163-7. doi: 10.1007/s11060-009-9863-y. Epub 2009 Mar 26.","Kast RE","J Neurooncol","2009","2009/03/27","","","10.1007/s11060-009-9863-y"
"19278178","Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients","Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, Zhukovsky DS, Stephenson R, Portenoy R, Stambler N, Israel R.","J Support Oncol. 2009 Jan-Feb;7(1):39-46.","Slatkin N","J Support Oncol","2009","2009/03/13","","",""
"19263773","Treating opioid-induced constipation with methylnaltrexone bromide","Kyle G.","Nurs Times. 2009 Feb 3-9;105(4):25.","Kyle G","Nurs Times","2009","2009/03/07","","",""
"19240629","Methylnaltrexone for opioid-induced constipation","Belavic JM.","Nurse Pract. 2009 Mar;34(3):6-7. doi: 10.1097/01.NPR.0000346585.18786.65.","Belavic JM","Nurse Pract","2009","2009/02/26","","","10.1097/01.NPR.0000346585.18786.65"
"19217656","Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus","Becker G, Blum HE.","Lancet. 2009 Apr 4;373(9670):1198-206. doi: 10.1016/S0140-6736(09)60139-2. Epub 2009 Feb 13.","Becker G","Lancet","2009","2009/02/17","","","10.1016/S0140-6736(09)60139-2"
"19155882","Drug approvals: '08 in review. Methylnaltrexone (Relistor)","Laustsen G, Carrillo F, Johnson J, Smith C.","Nurse Pract. 2009 Feb;34(2):31. doi: 10.1097/01.NPR.0000345271.43913.9f.","Laustsen G","Nurse Pract","2009","2009/01/22","","","10.1097/01.NPR.0000345271.43913.9f"
"19020145","Reversal of opioid-induced gastric dysfunction in a critically ill burn patient after methylnaltrexone","Woo M, O'Connor M, Yuan CS, Moss J.","Anesth Analg. 2008 Dec;107(6):1965-7. doi: 10.1213/ane.0b013e31818556d3.","Woo M","Anesth Analg","2008","2008/11/21","","","10.1213/ane.0b013e31818556d3"
"18826910","New drugs: methylnaltrexone bromide, alvimopan, and rilonacept","Hussar DA.","J Am Pharm Assoc (2003). 2008 Sep-Oct;48(5):688-91. doi: 10.1331/JAPhA.2008.08537.","Hussar DA","J Am Pharm Assoc (2003)","2008","2008/10/02","","","10.1331/JAPhA.2008.08537"
"18810678","[News from the cochrane library: mu opioid antagonists for opioid-induced bowel dysfunction]","Meerpohl JJ, Timmer A.","Z Gastroenterol. 2008 Sep;46(9):917-21. doi: 10.1055/s-2008-1027720. Epub 2008 Sep 22.","Meerpohl JJ","Z Gastroenterol","2008","2008/09/24","","","10.1055/s-2008-1027720"
"18777614","Methylnaltrexone for opioid-induced constipation in advanced illness","Chappell D, Rehm M, Conzen P.","N Engl J Med. 2008 Sep 4;359(10):1071; author reply 1071.","Chappell D","N Engl J Med","2008","2008/09/09","","",""
"18768955","Methylnaltrexone for opioid-induced constipation in advanced illness","Sanz Rubiales A, del Valle Rivero ML.","N Engl J Med. 2008 Sep 4;359(10):1070-1; author reply 1071. doi: 10.1056/NEJMc081373.","Sanz Rubiales A","N Engl J Med","2008","2008/09/05","","","10.1056/NEJMc081373"
"18694369","Methylnaltrexone, a new peripherally acting mu-opioid receptor antagonist being evaluated for the treatment of postoperative ileus","Kraft MD.","Expert Opin Investig Drugs. 2008 Sep;17(9):1365-77. doi: 10.1517/13543784.17.9.1365.","Kraft MD","Expert Opin Investig Drugs","2008","2008/08/13","","","10.1517/13543784.17.9.1365"
"18688204","Methylnaltrexone (Relistor) for opioid induced constipation","","Med Lett Drugs Ther. 2008 Aug 11;50(1292):63-4.","","Med Lett Drugs Ther","2008","2008/08/09","","",""
"18580669","Managing opioid-induced constipation","","Nursing. 2008 Jul;38(7):55. doi: 10.1097/01.NURSE.0000325349.32104.aa.","","Nursing","2008","2008/06/27","","","10.1097/01.NURSE.0000325349.32104.aa"
"18566238","Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis","Singleton PA, Garcia JG, Moss J.","Mol Cancer Ther. 2008 Jun;7(6):1669-79. doi: 10.1158/1535-7163.MCT-07-2217.","Singleton PA","Mol Cancer Ther","2008","2008/06/21","","","10.1158/1535-7163.MCT-07-2217"
"18549816","The Food and Drug Administration approves methylnaltrexone bromide for opioid-induced constipation","Lang L.","Gastroenterology. 2008 Jul;135(1):6. doi: 10.1053/j.gastro.2008.06.003. Epub 2008 Jun 10.","Lang L","Gastroenterology","2008","2008/06/14","","","10.1053/j.gastro.2008.06.003"
"18509126","Opioid side effects--mechanism-based therapy","Berde C, Nurko S.","N Engl J Med. 2008 May 29;358(22):2400-2. doi: 10.1056/NEJMe0801783.","Berde C","N Engl J Med","2008","2008/05/30","","","10.1056/NEJMe0801783"
"18509120","Methylnaltrexone for opioid-induced constipation in advanced illness","Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, Israel RJ.","N Engl J Med. 2008 May 29;358(22):2332-43. doi: 10.1056/NEJMoa0707377.","Thomas J","N Engl J Med","2008","2008/05/30","","","10.1056/NEJMoa0707377"
"18499867","Relistor approved for opioid-related constipation","Traynor K.","Am J Health Syst Pharm. 2008 Jun 1;65(11):996. doi: 10.2146/news080043.","Traynor K","Am J Health Syst Pharm","2008","2008/05/24","","","10.2146/news080043"
"18440447","Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study","Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, Von Gunten CF, Israel RJ.","J Pain Symptom Manage. 2008 May;35(5):458-68. doi: 10.1016/j.jpainsymman.2007.12.005.","Portenoy RK","J Pain Symptom Manage","2008","2008/04/29","","","10.1016/j.jpainsymman.2007.12.005"
"18425947","Mu-opioid antagonists for opioid-induced bowel dysfunction","McNicol ED, Boyce D, Schumann R, Carr DB.","Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006332. doi: 10.1002/14651858.CD006332.pub2.","McNicol ED","Cochrane Database Syst Rev","2008","2008/04/22","","","10.1002/14651858.CD006332.pub2"
"18223355","New therapies in the treatment of postoperative ileus after gastrointestinal surgery","Maron DJ, Fry RD.","Am J Ther. 2008 Jan-Feb;15(1):59-65. doi: 10.1097/MJT.0b013e31804c6f37.","Maron DJ","Am J Ther","2008","2008/01/29","","","10.1097/MJT.0b013e31804c6f37"
"18183536","Methylnaltrexone, a new peripheral mu-receptor antagonist for the prevention and treatment of opioid-induced extracerebral side effects","Reichle FM, Conzen PF.","Curr Opin Investig Drugs. 2008 Jan;9(1):90-100.","Reichle FM","Curr Opin Investig Drugs","2008","2008/01/10","","",""
"18022696","The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor","DeHaven-Hudkins DL, DeHaven RN, Little PJ, Techner LM.","Pharmacol Ther. 2008 Jan;117(1):162-87. doi: 10.1016/j.pharmthera.2007.09.007. Epub 2007 Oct 16.","DeHaven-Hudkins DL","Pharmacol Ther","2008","2007/11/21","","","10.1016/j.pharmthera.2007.09.007"
"17844725","Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus","Neyens R, Jackson KC 2nd.","J Pain Palliat Care Pharmacother. 2007;21(2):27-33.","Neyens R","J Pain Palliat Care Pharmacother","2007","2007/09/12","","",""
"17588352","Cancer-related constipation","Thomas J.","Curr Oncol Rep. 2007 Jul;9(4):278-84. doi: 10.1007/s11912-007-0034-z.","Thomas J","Curr Oncol Rep","2007","2007/06/26","","","10.1007/s11912-007-0034-z"
"17578067","A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation","Shaiova L, Rim F, Friedman D, Jahdi M.","Palliat Support Care. 2007 Jun;5(2):161-6. doi: 10.1017/s147895150707023x.","Shaiova L","Palliat Support Care","2007","2007/06/21","","","10.1017/s147895150707023x"
"17504835","Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects","Yuan CS.","Ann Pharmacother. 2007 Jun;41(6):984-93. doi: 10.1345/aph.1K009. Epub 2007 May 15.","Yuan CS","Ann Pharmacother","2007","2007/05/17","","","10.1345/aph.1K009"
"17395891","Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation","Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG.","Am J Respir Cell Mol Biol. 2007 Aug;37(2):222-31. doi: 10.1165/rcmb.2006-0327OC. Epub 2007 Mar 29.","Singleton PA","Am J Respir Cell Mol Biol","2007","2007/03/31","","","10.1165/rcmb.2006-0327OC"
"17392726","Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone","Rosow CE, Gomery P, Chen TY, Stefanovich P, Stambler N, Israel R.","Clin Pharmacol Ther. 2007 Jul;82(1):48-53. doi: 10.1038/sj.clpt.6100164. Epub 2007 Mar 28.","Rosow CE","Clin Pharmacol Ther","2007","2007/03/30","","","10.1038/sj.clpt.6100164"
"17340127","The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone","Beattie DT, Cheruvu M, Mai N, O'Keefe M, Johnson-Rabidoux S, Peterson C, Kaufman E, Vickery R.","Naunyn Schmiedebergs Arch Pharmacol. 2007 May;375(3):205-20. doi: 10.1007/s00210-007-0146-x. Epub 2007 Mar 6.","Beattie DT","Naunyn Schmiedebergs Arch Pharmacol","2007","2007/03/07","","","10.1007/s00210-007-0146-x"
"17105998","Pain management research goes beyond the obvious","Thompson CA.","Am J Health Syst Pharm. 2006 Dec 1;63(23):2298, 2302, 2304. doi: 10.2146/news060027.","Thompson CA","Am J Health Syst Pharm","2006","2006/11/16","","","10.2146/news060027"
"17073520","Methylnaltrexone: MNTX","","Drugs R D. 2006;7(6):374-8. doi: 10.2165/00126839-200607060-00006.","","Drugs R D","2006","2006/11/01","","","10.2165/00126839-200607060-00006"
"16820176","Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation","Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J.","Microvasc Res. 2006 Jul-Sep;72(1-2):3-11. doi: 10.1016/j.mvr.2006.04.004. Epub 2006 Jul 3.","Singleton PA","Microvasc Res","2006","2006/07/06","","","10.1016/j.mvr.2006.04.004"
"16797494","The selective mu opioid receptor antagonist, alvimopan, improves delayed GI transit of postoperative ileus in rats","Fukuda H, Suenaga K, Tsuchida D, Mantyh CR, Pappas TN, Hicks GA, Dehaven-Hudkins DL, Takahashi T.","Brain Res. 2006 Aug 2;1102(1):63-70. doi: 10.1016/j.brainres.2006.02.092. Epub 2006 Jun 22.","Fukuda H","Brain Res","2006","2006/06/27","","","10.1016/j.brainres.2006.02.092"
"16740093","Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine","Boscan P, Van Hoogmoed LM, Pypendop BH, Farver TB, Snyder JR.","Am J Vet Res. 2006 Jun;67(6):998-1004. doi: 10.2460/ajvr.67.6.998.","Boscan P","Am J Vet Res","2006","2006/06/03","","","10.2460/ajvr.67.6.998"
"16634692","Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects","Yuan CS, Israel RJ.","Expert Opin Investig Drugs. 2006 May;15(5):541-52. doi: 10.1517/13543784.15.5.541.","Yuan CS","Expert Opin Investig Drugs","2006","2006/04/26","","","10.1517/13543784.15.5.541"
"16597534","Current choices--good or bad--for the proactive management of postoperative ileus: A surgeon's view","Saclarides TJ.","J Perianesth Nurs. 2006 Apr;21(2A Suppl):S7-15. doi: 10.1016/j.jopan.2006.01.008.","Saclarides TJ","J Perianesth Nurs","2006","2006/04/07","","","10.1016/j.jopan.2006.01.008"
"16597532","The surgical team and outcomes management: focus on postoperative ileus","Carter S.","J Perianesth Nurs. 2006 Apr;21(2A Suppl):S2-6. doi: 10.1016/j.jopan.2006.01.012.","Carter S","J Perianesth Nurs","2006","2006/04/07","","","10.1016/j.jopan.2006.01.012"
"16597531","Peripherally acting mu-opioid-receptor antagonists and the connection between postoperative ileus and pain management: The anesthesiologist's view and beyond","Sinatra RS.","J Perianesth Nurs. 2006 Apr;21(2A Suppl):S16-23. doi: 10.1016/j.jopan.2006.01.016.","Sinatra RS","J Perianesth Nurs","2006","2006/04/07","","","10.1016/j.jopan.2006.01.016"
"16028621","In vitro evaluation of the effect of the opioid antagonist N-methylnaltrexone on motility of the equine jejunum and pelvic flexure","van Hoogmoed LM, Boscan PL.","Equine Vet J. 2005 Jul;37(4):325-8. doi: 10.2746/0425164054529346.","van Hoogmoed LM","Equine Vet J","2005","2005/07/21","","","10.2746/0425164054529346"
"15831777","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans","Yuan CS, Doshan H, Charney MR, O'connor M, Karrison T, Maleckar SA, Israel RJ, Moss J.","J Clin Pharmacol. 2005 May;45(5):538-46. doi: 10.1177/0091270004273491.","Yuan CS","J Clin Pharmacol","2005","2005/04/16","","","10.1177/0091270004273491"
"15328815","Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects","Yuan CS.","J Support Oncol. 2004 Mar-Apr;2(2):111-7; discussion 119-22.","Yuan CS","J Support Oncol","2004","2004/08/27","","",""
"15135926","Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans","Holzer P.","Neurosci Lett. 2004 May 6;361(1-3):192-5. doi: 10.1016/j.neulet.2003.12.004.","Holzer P","Neurosci Lett","2004","2004/05/12","","","10.1016/j.neulet.2003.12.004"
"15043984","Methylnaltrexone prevents morphine-induced kaolin intake in the rat","Aung HH, Mehendale SR, Xie JT, Moss J, Yuan CS.","Life Sci. 2004 Apr 16;74(22):2685-91. doi: 10.1016/j.lfs.2003.08.047.","Aung HH","Life Sci","2004","2004/03/27","","","10.1016/j.lfs.2003.08.047"
"14634035","Opioid partial agonist effects of 3-O-methylnaltrexone in rhesus monkeys","Platt DM, Rowlett JK, Izenwasser S, Spealman RD.","J Pharmacol Exp Ther. 2004 Mar;308(3):1030-9. doi: 10.1124/jpet.103.060962. Epub 2003 Nov 21.","Platt DM","J Pharmacol Exp Ther","2004","2003/11/25","","","10.1124/jpet.103.060962"
"14560041","Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes","Ho WZ, Guo CJ, Yuan CS, Douglas SD, Moss J.","J Pharmacol Exp Ther. 2003 Dec;307(3):1158-62. doi: 10.1124/jpet.103.056697. Epub 2003 Oct 14.","Ho WZ","J Pharmacol Exp Ther","2003","2003/10/16","PMC4016816","NIHMS575103","10.1124/jpet.103.056697"
"14502469","Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics","Button WG, Judson PN, Long A, Vessey JD.","J Chem Inf Comput Sci. 2003 Sep-Oct;43(5):1371-7. doi: 10.1021/ci0202739.","Button WG","J Chem Inf Comput Sci","2003","2003/09/23","","","10.1021/ci0202739"
"12656645","Opioid-induced bowel dysfunction: pathophysiology and potential new therapies","Kurz A, Sessler DI.","Drugs. 2003;63(7):649-71. doi: 10.2165/00003495-200363070-00003.","Kurz A","Drugs","2003","2003/03/27","","","10.2165/00003495-200363070-00003"
"12401350","Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study","Osinski J, Wang A, Wu JA, Foss JF, Yuan CS.","J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):251-9. doi: 10.1016/s1570-0232(02)00527-5.","Osinski J","J Chromatogr B Analyt Technol Biomed Life Sci","2002","2002/10/29","","","10.1016/s1570-0232(02)00527-5"
"12090733","Methylnaltrexone Progenics","De Ponti F.","Curr Opin Investig Drugs. 2002 Apr;3(4):614-20.","De Ponti F","Curr Opin Investig Drugs","2002","2002/07/02","","",""
"12084520","Differential antagonism of endomorphin-1 and endomorphin-2 supraspinal antinociception by naloxonazine and 3-methylnaltrexone","Sakurada S, Hayashi T, Yuhki M, Fujimura T, Murayama K, Yonezawa A, Sakurada C, Takeshita M, Sato T, Zadina JE, Kastin AJ, Sakurada T.","Peptides. 2002 May;23(5):895-901. doi: 10.1016/s0196-9781(02)00016-5.","Sakurada S","Peptides","2002","2002/06/27","","","10.1016/s0196-9781(02)00016-5"
"12067677","Methylnaltrexone reverses opioid-induced constipation","Stephenson J.","Lancet Oncol. 2002 Apr;3(4):202. doi: 10.1016/s1470-2045(02)00706-4.","Stephenson J","Lancet Oncol","2002","2002/06/18","","","10.1016/s1470-2045(02)00706-4"
"11832541","Selective postoperative inhibition of gastrointestinal opioid receptors","Moss J, Yuan CS.","N Engl J Med. 2002 Feb 7;346(6):455. doi: 10.1056/NEJM200202073460617.","Moss J","N Engl J Med","2002","2002/02/08","","","10.1056/NEJM200202073460617"
"11755893","A review of the potential role of methylnaltrexone in opioid bowel dysfunction","Foss JF.","Am J Surg. 2001 Nov;182(5A Suppl):19S-26S. doi: 10.1016/s0002-9610(01)00783-8.","Foss JF","Am J Surg","2001","2002/01/05","","","10.1016/s0002-9610(01)00783-8"
"11755892","Incidence, prevalence, and management of opioid bowel dysfunction","Pappagallo M.","Am J Surg. 2001 Nov;182(5A Suppl):11S-18S. doi: 10.1016/s0002-9610(01)00782-6.","Pappagallo M","Am J Surg","2001","2002/01/05","","","10.1016/s0002-9610(01)00782-6"
"11752106","Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial","Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, Osinski J.","J Pharmacol Exp Ther. 2002 Jan;300(1):118-23. doi: 10.1124/jpet.300.1.118.","Yuan CS","J Pharmacol Exp Ther","2002","2001/12/26","","","10.1124/jpet.300.1.118"
"11575386","Pharmacokinetic profile of epidurally administered methylnaltrexone, a novel peripheral opioid antagonist in a rabbit model","Murph DB, El Behiery H, Chan VW, Foss JF.","Br J Anaesth. 2001 Jan;86(1):120-2. doi: 10.1093/bja/86.1.120.","Murph DB","Br J Anaesth","2001","2001/09/29","","","10.1093/bja/86.1.120"
"11282159","Involvement of substance P and central opioid receptors in morphine modulation of the CHS response","Nelson CJ, Lysle DT.","J Neuroimmunol. 2001 Apr 2;115(1-2):101-10. doi: 10.1016/s0165-5728(01)00258-2.","Nelson CJ","J Neuroimmunol","2001","2001/04/03","","","10.1016/s0165-5728(01)00258-2"
"11197589","Opioid antagonists in the treatment of opioid-induced constipation and pruritus","Friedman JD, Dello Buono FA.","Ann Pharmacother. 2001 Jan;35(1):85-91. doi: 10.1345/aph.10121.","Friedman JD","Ann Pharmacother","2001","2001/02/24","","","10.1345/aph.10121"
"11097674","Antagonism of gastrointestinal opioid effects","Yuan CS, Foss JF.","Reg Anesth Pain Med. 2000 Nov-Dec;25(6):639-42. doi: 10.1053/rapm.2000.8658.","Yuan CS","Reg Anesth Pain Med","2000","2000/11/30","","","10.1053/rapm.2000.8658"
"10989399","Oral methylnaltrexone for opioid-induced constipation","Yuan CS, Foss JF.","JAMA. 2000 Sep 20;284(11):1383-4. doi: 10.1001/jama.284.11.1383.","Yuan CS","JAMA","2000","2000/09/16","","","10.1001/jama.284.11.1383"
"10970678","Involvement of central mu- but not delta- or kappa-opioid receptors in immunomodulation","Nelson CJ, Schneider GM, Lysle DT.","Brain Behav Immun. 2000 Sep;14(3):170-84. doi: 10.1006/brbi.1999.0575.","Nelson CJ","Brain Behav Immun","2000","2000/09/06","","","10.1006/brbi.1999.0575"
"10897756","Managing constipation that's opioid-induced","Scholz M.","RN. 2000 Jun;63(6):103.","Scholz M","RN","2000","2000/07/18","","",""
"10806416","Morphine tolerance in mice changes response of heroin from mu to delta opioid receptors","Rady JJ, Holmes BB, Portoghese PS, Fujimoto JM.","Proc Soc Exp Biol Med. 2000 Jun;224(2):93-101. doi: 10.1046/j.1525-1373.2000.22406.x.","Rady JJ","Proc Soc Exp Biol Med","2000","2000/05/12","","","10.1046/j.1525-1373.2000.22406.x"
"10801249","Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time","Yuan CS, Foss JF, O'Connor M, Karrison T, Osinski J, Roizen MF, Moss J.","Clin Pharmacol Ther. 2000 Apr;67(4):398-404. doi: 10.1067/mcp.2000.105037.","Yuan CS","Clin Pharmacol Ther","2000","2000/05/09","","","10.1067/mcp.2000.105037"
"10789883","Acute exposure to saccharin reduces morphine analgesia in the the rat: evidence for involvement of N-methyl-D-aspartate and peripheral opioid receptors","McNally GP, Westbrook RF.","Psychopharmacology (Berl). 2000 Mar;149(1):56-62. doi: 10.1007/s002139900337.","McNally GP","Psychopharmacology (Berl)","2000","2000/05/02","","","10.1007/s002139900337"
"10647800","Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial","Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, Roizen MF.","JAMA. 2000 Jan 19;283(3):367-72. doi: 10.1001/jama.283.3.367.","Yuan CS","JAMA","2000","2000/01/27","","","10.1001/jama.283.3.367"
"10585524","Antagonism of heroin and morphine self-administration in rats by the morphine-6beta-glucuronide antagonist 3-O-methylnaltrexone","Walker JR, King M, Izzo E, Koob GF, Pasternak GW.","Eur J Pharmacol. 1999 Oct 27;383(2):115-9. doi: 10.1016/s0014-2999(99)00633-0.","Walker JR","Eur J Pharmacol","1999","1999/12/11","","","10.1016/s0014-2999(99)00633-0"
"10568873","Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study","Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J.","Pain. 1999 Dec;83(3):631-5. doi: 10.1016/s0304-3959(99)00162-1.","Yuan CS","Pain","1999","1999/11/24","","","10.1016/s0304-3959(99)00162-1"
"10456559","Peripheral opioid receptors may mediate a portion of the aversive and depressant effect of EtOH: CPP and locomotor activity","Bedingfield JB, King DA, Holloway FA.","Alcohol. 1999 Jun-Jul;18(2-3):93-101. doi: 10.1016/s0741-8329(98)00054-8.","Bedingfield JB","Alcohol","1999","1999/08/24","","","10.1016/s0741-8329(98)00054-8"
"10219980","Gastric effects of methylnaltrexone on mu, kappa, and delta opioid agonists induced brainstem unitary responses","Yuan CS, Foss JF.","Neuropharmacology. 1999 Mar;38(3):425-32. doi: 10.1016/s0028-3908(98)00192-0.","Yuan CS","Neuropharmacology","1999","1999/04/29","","","10.1016/s0028-3908(98)00192-0"
"9918551","Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes","Lysle DT, How T.","J Pharmacol Exp Ther. 1999 Feb;288(2):502-8.","Lysle DT","J Pharmacol Exp Ther","1999","1999/01/26","","",""
"9890406","Opioid antagonist modulation of ischaemia-induced ventricular arrhythmias: a peripheral mechanism","Murphy DB, Murphy MB.","J Cardiovasc Pharmacol. 1999 Jan;33(1):122-5. doi: 10.1097/00005344-199901000-00018.","Murphy DB","J Cardiovasc Pharmacol","1999","1999/01/16","","","10.1097/00005344-199901000-00018"
"9800145","Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine","Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J.","Drug Alcohol Depend. 1998 Oct 1;52(2):161-5. doi: 10.1016/s0376-8716(98)00087-8.","Yuan CS","Drug Alcohol Depend","1998","1998/11/04","","","10.1016/s0376-8716(98)00087-8"
"9744773","Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine","Foss JF, Yuan CS, Roizen MF, Goldberg LI.","Cancer Chemother Pharmacol. 1998;42(4):287-91. doi: 10.1007/s002800050819.","Foss JF","Cancer Chemother Pharmacol","1998","1998/09/23","","","10.1007/s002800050819"
"9726837","Role of central mu-opioid receptors in the modulation of nitric oxide production by splenocytes","Schneider GM, Lysle DT.","J Neuroimmunol. 1998 Aug 14;89(1-2):150-9. doi: 10.1016/s0165-5728(98)00128-3.","Schneider GM","J Neuroimmunol","1998","1998/09/03","","","10.1016/s0165-5728(98)00128-3"
"9712411","The effect of acute stress and opioid antagonist on the activity of NADPH-P450 reductase in rat Leydig cells","Kostić T, Andrić S, Marić D, Kovacević R.","J Steroid Biochem Mol Biol. 1998 Jul;66(1-2):51-4. doi: 10.1016/s0960-0760(98)00003-x.","Kostić T","J Steroid Biochem Mol Biol","1998","1998/08/26","","","10.1016/s0960-0760(98)00003-x"
"9426837","Methylnaltrexone attenuates taste aversion conditioned by low-dose ethanol","Bedingfield JB, Holloway FA.","Alcohol. 1998 Jan;15(1):51-4. doi: 10.1016/s0741-8329(97)00097-9.","Bedingfield JB","Alcohol","1998","1998/01/14","","","10.1016/s0741-8329(97)00097-9"
"9366009","The effect of opioid antagonists in local regulation of testicular response to acute stress in adult rats","Kostić T, Andrić S, Kovacević R, Marić D.","Steroids. 1997 Nov;62(11):703-8. doi: 10.1016/s0039-128x(97)00071-8.","Kostić T","Steroids","1997","1997/11/20","","","10.1016/s0039-128x(97)00071-8"
"9357876","Opioid-induced delay in gastric emptying: a peripheral mechanism in humans","Murphy DB, Sutton JA, Prescott LF, Murphy MB.","Anesthesiology. 1997 Oct;87(4):765-70. doi: 10.1097/00000542-199710000-00008.","Murphy DB","Anesthesiology","1997","1997/11/14","","","10.1097/00000542-199710000-00008"
"9357871","Methylnaltrexone: reversing the gastrointestinal effects of opioids","Rosow CE.","Anesthesiology. 1997 Oct;87(4):736-7. doi: 10.1097/00000542-199710000-00003.","Rosow CE","Anesthesiology","1997","1997/11/14","","","10.1097/00000542-199710000-00003"
"9129564","The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time","Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J.","Clin Pharmacol Ther. 1997 Apr;61(4):467-75. doi: 10.1016/S0009-9236(97)90197-1.","Yuan CS","Clin Pharmacol Ther","1997","1997/04/01","","","10.1016/S0009-9236(97)90197-1"
"9048269","Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study","Foss JF, O'Connor MF, Yuan CS, Murphy M, Moss J, Roizen MF.","J Clin Pharmacol. 1997 Jan;37(1):25-30. doi: 10.1177/009127009703700105.","Foss JF","J Clin Pharmacol","1997","1997/01/01","","","10.1177/009127009703700105"
"8985972","Cancer pain remedy wins orphan drug status","","Oncology (Williston Park). 1996 Dec;10(12):1880.","","Oncology (Williston Park)","1996","1996/12/01","","",""
"8905323","Systemic administration of dynorphin A-(1-13) markedly improves cycloheximide-induced amnesia in mice","Ukai M, Shan-Wu X, Kobayashi T, Kameyama T.","Eur J Pharmacol. 1996 Oct 10;313(1-2):11-5. doi: 10.1016/0014-2999(96)00484-0.","Ukai M","Eur J Pharmacol","1996","1996/10/10","","","10.1016/0014-2999(96)00484-0"
"8845013","Effects of methylnaltrexone on morphine-induced cough suppression in guinea pigs","Foss JF, Orelind E, Goldberg LI.","Life Sci. 1996;59(15):PL235-8. doi: 10.1016/0024-3205(96)00451-1.","Foss JF","Life Sci","1996","1996/01/01","","","10.1016/0024-3205(96)00451-1"
"8669218","Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences","Moerman I, Franck P, Camu F.","Acta Anaesthesiol Belg. 1995;46(3-4):127-32.","Moerman I","Acta Anaesthesiol Belg","1995","1995/01/01","","",""
"8612393","Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial","Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J.","Clin Pharmacol Ther. 1996 Apr;59(4):469-75. doi: 10.1016/S0009-9236(96)90117-4.","Yuan CS","Clin Pharmacol Ther","1996","1996/04/01","","","10.1016/S0009-9236(96)90117-4"
"8408737","Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs","Foss JF, Bass AS, Goldberg LI.","J Clin Pharmacol. 1993 Aug;33(8):747-51. doi: 10.1002/j.1552-4604.1993.tb05618.x.","Foss JF","J Clin Pharmacol","1993","1993/08/01","","","10.1002/j.1552-4604.1993.tb05618.x"
"8202214","Effect of a peripheral and a central acting opioid antagonist on the testicular response to stress in rats","Akinbami MA, Taylor MF, Collins DC, Mann DR.","Neuroendocrinology. 1994 Apr;59(4):343-8. doi: 10.1159/000126676.","Akinbami MA","Neuroendocrinology","1994","1994/04/01","","","10.1159/000126676"
"8135389","Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response","Amin HM, Sopchak AM, Foss JF, Esposito BF, Roizen MF, Camporesi EM.","Anesth Analg. 1994 Apr;78(4):701-5. doi: 10.1213/00000539-199404000-00015.","Amin HM","Anesth Analg","1994","1994/04/01","","","10.1213/00000539-199404000-00015"
"7900916","Role of endogenous central opioid mechanisms in maintenance of body sodium balance","Kapusta DR, Obih JC.","Am J Physiol. 1995 Mar;268(3 Pt 2):R723-30. doi: 10.1152/ajpregu.1995.268.3.R723.","Kapusta DR","Am J Physiol","1995","1995/03/01","","","10.1152/ajpregu.1995.268.3.R723"
"7781680","Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine","Yuan CS, Foss JF, Moss J.","Eur J Pharmacol. 1995 Mar 24;276(1-2):107-11. doi: 10.1016/0014-2999(95)00018-g.","Yuan CS","Eur J Pharmacol","1995","1995/03/24","","","10.1016/0014-2999(95)00018-g"
"7700837","GRF-induced feeding: evidence for protein selectivity and opiate involvement","Dickson PR, Vaccarino FJ.","Peptides. 1994;15(8):1343-52. doi: 10.1016/0196-9781(94)90107-4.","Dickson PR","Peptides","1994","1994/01/01","","","10.1016/0196-9781(94)90107-4"
"7667374","Effects of restraint stress and intra-ventral tegmental area injections of morphine and methyl naltrexone on the discriminative stimulus effects of heroin in the rat","Shaham Y, Stewart J.","Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):491-8. doi: 10.1016/0091-3057(95)00015-o.","Shaham Y","Pharmacol Biochem Behav","1995","1995/06/01","","","10.1016/0091-3057(95)00015-o"
"7284781","Opiate antagonists: central sites of action in suppressing water intake of the rat","Brown DR, Holtzman SG.","Brain Res. 1981 Sep 28;221(2):432-6. doi: 10.1016/0006-8993(81)90796-4.","Brown DR","Brain Res","1981","1981/09/28","","","10.1016/0006-8993(81)90796-4"
"6843782","Effects of naloxone and its quarternary analogue on stimulation-induced feeding","Carr KD, Simon EJ.","Neuropharmacology. 1983 Jan;22(1):127-30. doi: 10.1016/0028-3908(83)90272-1.","Carr KD","Neuropharmacology","1983","1983/01/01","","","10.1016/0028-3908(83)90272-1"
"6716270","Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat","Koob GF, Pettit HO, Ettenberg A, Bloom FE.","J Pharmacol Exp Ther. 1984 May;229(2):481-6.","Koob GF","J Pharmacol Exp Ther","1984","1984/05/01","","",""
"6682490","Reversal of morphine-induced catalepsy in the rat by narcotic antagonists and their quaternary derivatives","Brown DR, Robertson MJ, Goldberg LI.","Neuropharmacology. 1983 Mar;22(3):317-21. doi: 10.1016/0028-3908(83)90246-0.","Brown DR","Neuropharmacology","1983","1983/03/01","","","10.1016/0028-3908(83)90246-0"
"6640302","Interaction of the opiate antagonist, naltrexone methyl bromide, with the acetylcholine receptor system of the motor end-plate","Argentieri TM, McArdle JJ.","Brain Res. 1983 Oct 31;277(2):377-9. doi: 10.1016/0006-8993(83)90950-2.","Argentieri TM","Brain Res","1983","1983/10/31","","","10.1016/0006-8993(83)90950-2"
"6607339","An antiabsorptive basis for precipitated withdrawal diarrhea in morphine-dependent rats","Chang EB, Brown DR, Field M, Miller RJ.","J Pharmacol Exp Ther. 1984 Feb;228(2):364-9.","Chang EB","J Pharmacol Exp Ther","1984","1984/02/01","","",""
"6578730","Endorphins in endotoxin-induced hyperglycemia in mice","Amir S, Harel M.","Arch Toxicol Suppl. 1983;6:261-5. doi: 10.1007/978-3-642-69083-9_48.","Amir S","Arch Toxicol Suppl","1983","1983/01/01","","","10.1007/978-3-642-69083-9_48"
"6543435","Opioid involvement in hypertension induced by short-term isolation","Fuentes JA, Borrell J, Naranjo JR.","Clin Exp Hypertens A. 1984;6(10-11):2041-4. doi: 10.3109/10641968409046124.","Fuentes JA","Clin Exp Hypertens A","1984","1984/01/01","","","10.3109/10641968409046124"
"6183549","Effects of N-methylnaloxone and N-methylnaltrexone on nociception and precipitated abstinence in mice","Ramabadran K.","Life Sci. 1982 Sep 20-27;31(12-13):1253-6. doi: 10.1016/0024-3205(82)90355-1.","Ramabadran K","Life Sci","1982","1982/09/20","","","10.1016/0024-3205(82)90355-1"
"4070392","Quaternary naltrexone reverses morphine-induced behaviors","Mickley GA, Stevens KE, Galbraith JA.","Physiol Behav. 1985 Aug;35(2):249-53. doi: 10.1016/0031-9384(85)90345-2.","Mickley GA","Physiol Behav","1985","1985/08/01","","","10.1016/0031-9384(85)90345-2"
"4033357","Narcotic antagonist-induced hypotension in the spontaneously hypertensive rat","Quock RM, Kouchich FJ, Vaughn LK, Fries DS.","Life Sci. 1985 Sep 2;37(9):819-26. doi: 10.1016/0024-3205(85)90516-8.","Quock RM","Life Sci","1985","1985/09/02","","","10.1016/0024-3205(85)90516-8"
"3927336","Central and peripheral contributions of endogenous opioid systems to nutrient selection in rats","Marks-Kaufman R, Plager A, Kanarek RB.","Psychopharmacology (Berl). 1985;85(4):414-8. doi: 10.1007/BF00429656.","Marks-Kaufman R","Psychopharmacology (Berl)","1985","1985/01/01","","","10.1007/BF00429656"
"3713432","Evidence for a central but not adrenal, opioid mediation in hypertension induced by brief isolation in the rat","Naranjo JR, Urdín MC, Borrell J, Fuentes JA.","Life Sci. 1986 May 26;38(21):1923-30. doi: 10.1016/0024-3205(86)90221-3.","Naranjo JR","Life Sci","1986","1986/05/26","","","10.1016/0024-3205(86)90221-3"
"3690365","Effects of opiate antagonist treatment into either the periaqueductal grey or nucleus accumbens on heroin-induced locomotor activation","Vaccarino FJ, Corrigall WA.","Brain Res Bull. 1987 Nov;19(5):545-9. doi: 10.1016/0361-9230(87)90071-2.","Vaccarino FJ","Brain Res Bull","1987","1987/11/01","","","10.1016/0361-9230(87)90071-2"
"3676713","Is the motivational effect of opiate withdrawal reflected by common somatic indices of precipitated withdrawal? A place conditioning study in the rat","Mucha RF.","Brain Res. 1987 Aug 25;418(2):214-20. doi: 10.1016/0006-8993(87)90088-6.","Mucha RF","Brain Res","1987","1987/08/25","","","10.1016/0006-8993(87)90088-6"
"3659093","Heroin self-administration: effects of antagonist treatment in lateral hypothalamus","Corrigall WA.","Pharmacol Biochem Behav. 1987 Aug;27(4):693-700. doi: 10.1016/0091-3057(87)90196-1.","Corrigall WA","Pharmacol Biochem Behav","1987","1987/08/01","","","10.1016/0091-3057(87)90196-1"
"3620936","Enkephalin release into the ventral tegmental area in response to stress: modulation of mesocorticolimbic dopamine","Kalivas PW, Abhold R.","Brain Res. 1987 Jun 30;414(2):339-48. doi: 10.1016/0006-8993(87)90015-1.","Kalivas PW","Brain Res","1987","1987/06/30","","","10.1016/0006-8993(87)90015-1"
"3601009","Comparison of naltrexone and quaternary naltrexone after systemic and intracerebroventricular administration in pigeons","France CP, Adams JU, Woods JH.","Neuropharmacology. 1987 Jun;26(6):541-8. doi: 10.1016/0028-3908(87)90145-6.","France CP","Neuropharmacology","1987","1987/06/01","","","10.1016/0028-3908(87)90145-6"
"3420162","Evidence for the involvement of central opioidergic systems in L-tyrosine methyl ester-induced analgesia in the rat","Ramarao P, Bhargava HN.","Pharmacology. 1988;37(1):1-7. doi: 10.1159/000138407.","Ramarao P","Pharmacology","1988","1988/01/01","","","10.1159/000138407"
"3211978","Morphine preexposure attenuates the aversive properties of opiates without preexposure to the aversive properties","Martin GM, Bechara A, van der Kooy D.","Pharmacol Biochem Behav. 1988 Jul;30(3):687-92. doi: 10.1016/0091-3057(88)90085-8.","Martin GM","Pharmacol Biochem Behav","1988","1988/07/01","","","10.1016/0091-3057(88)90085-8"
"3174777","Antagonist treatment in nucleus accumbens or periaqueductal grey affects heroin self-administration","Corrigall WA, Vaccarino FJ.","Pharmacol Biochem Behav. 1988 Jun;30(2):443-50. doi: 10.1016/0091-3057(88)90478-9.","Corrigall WA","Pharmacol Biochem Behav","1988","1988/06/01","","","10.1016/0091-3057(88)90478-9"
"3088658","An analysis of the paradoxical effect of morphine on runway speed and food consumption","Corrigall WA, Linseman MA, D'Onofrio RM, Lei H.","Psychopharmacology (Berl). 1986;89(3):327-33. doi: 10.1007/BF00174369.","Corrigall WA","Psychopharmacology (Berl)","1986","1986/01/01","","","10.1007/BF00174369"
"3039272","Role of peripheral and central opioid activity in analgesia induced by restraint stress","Kelly SJ, Franklin KB.","Life Sci. 1987 Aug 10;41(6):789-94. doi: 10.1016/0024-3205(87)90460-7.","Kelly SJ","Life Sci","1987","1987/08/10","","","10.1016/0024-3205(87)90460-7"
"3020332","Central, stereoselective receptors mediate the acute effects of opiate antagonists on luteinizing hormone secretion","Blank MS, Mann DR, Daugherty DT, Sridiran R, Murphy JR.","Life Sci. 1986 Oct 27;39(17):1493-99. doi: 10.1016/0024-3205(86)90378-4.","Blank MS","Life Sci","1986","1986/10/27","","","10.1016/0024-3205(86)90378-4"
"3014971","Hyperalgesic functions of peripheral opiate receptors","van der Kooy D.","Ann N Y Acad Sci. 1986;467:154-68. doi: 10.1111/j.1749-6632.1986.tb14626.x.","van der Kooy D","Ann N Y Acad Sci","1986","1986/01/01","","","10.1111/j.1749-6632.1986.tb14626.x"
"2997824","Characterization of the discriminative stimulus effects of centrally administered morphine in the rat","Locke KW, Holtzman SG.","Psychopharmacology (Berl). 1985;87(1):1-6. doi: 10.1007/BF00431767.","Locke KW","Psychopharmacology (Berl)","1985","1985/01/01","","","10.1007/BF00431767"
"2986002","Opposite motivational effects of endogenous opioids in brain and periphery","Bechara A, van der Kooy D.","Nature. 1985 Apr 11-17;314(6011):533-4. doi: 10.1038/314533a0.","Bechara A","Nature","1985","1985/04/11","","","10.1038/314533a0"
"2935140","Pharmacological evidence of a central effect of naltrexone, morphine, and beta-endorphin and a peripheral effect of met- and leu-enkephalin on retention of an inhibitory response in mice","Introini IB, McGaugh JL, Baratti CM.","Behav Neural Biol. 1985 Nov;44(3):434-46. doi: 10.1016/s0163-1047(85)90832-5.","Introini IB","Behav Neural Biol","1985","1985/11/01","","","10.1016/s0163-1047(85)90832-5"
"2901674","Evidence for a peripheral action of thyrotropin releasing hormone on gastrointestinal transit in mice","Bansinath M, Bhargava HN.","Neuropharmacology. 1988 Apr;27(4):433-7. doi: 10.1016/0028-3908(88)90153-0.","Bansinath M","Neuropharmacology","1988","1988/04/01","","","10.1016/0028-3908(88)90153-0"
"2883290","Intravenous kinetics and metabolism of [15,16-3H]naltrexonium methiodide in the rat","Misra AL, Pontani RB, Vadlamani NL.","J Pharm Pharmacol. 1987 Mar;39(3):225-7. doi: 10.1111/j.2042-7158.1987.tb06254.x.","Misra AL","J Pharm Pharmacol","1987","1987/03/01","","","10.1111/j.2042-7158.1987.tb06254.x"
"2846978","Central pharmacological activity of a quaternary ammonium compound in streptozotocin diabetic mice","Quock RM, Ishii MM, Emmanouil DE.","Life Sci. 1988;43(17):1411-7. doi: 10.1016/0024-3205(88)90308-6.","Quock RM","Life Sci","1988","1988/01/01","","","10.1016/0024-3205(88)90308-6"
"2831341","Roles of central and peripheral mu, delta and kappa opioid receptors in the mediation of gastric acid secretory effects in the rat","Fox DA, Burks TF.","J Pharmacol Exp Ther. 1988 Feb;244(2):456-62.","Fox DA","J Pharmacol Exp Ther","1988","1988/02/01","","",""
"2825220","Peripheral receptors mediate the aversive conditioning effects of morphine in the rat","Bechara A, Zito KA, van der Kooy D.","Pharmacol Biochem Behav. 1987 Oct;28(2):219-25. doi: 10.1016/0091-3057(87)90218-8.","Bechara A","Pharmacol Biochem Behav","1987","1987/10/01","","","10.1016/0091-3057(87)90218-8"
"2823789","The impairment of retention induced by pentylenetetrazol in mice may be mediated by a release of opioid peptides in the brain","Baratti CM.","Behav Neural Biol. 1987 Sep;48(2):183-96. doi: 10.1016/s0163-1047(87)90724-2.","Baratti CM","Behav Neural Biol","1987","1987/09/01","","","10.1016/s0163-1047(87)90724-2"
"2821555","Quaternary naltrexone reveals the central mediation of conditional opioid analgesia","Calcagnetti DJ, Helmstetter FJ, Fanselow MS.","Pharmacol Biochem Behav. 1987 Jul;27(3):529-31. doi: 10.1016/0091-3057(87)90360-1.","Calcagnetti DJ","Pharmacol Biochem Behav","1987","1987/07/01","","","10.1016/0091-3057(87)90360-1"
"2813479","Central vs. peripheral mediation of opioid effects on alcohol consumption in free-feeding rats","Linseman MA.","Pharmacol Biochem Behav. 1989 Jun;33(2):407-13. doi: 10.1016/0091-3057(89)90523-6.","Linseman MA","Pharmacol Biochem Behav","1989","1989/06/01","","","10.1016/0091-3057(89)90523-6"
"2795130","The tegmental pedunculopontine nucleus: a brain-stem output of the limbic system critical for the conditioned place preferences produced by morphine and amphetamine","Bechara A, van der Kooy D.","J Neurosci. 1989 Oct;9(10):3400-9. doi: 10.1523/JNEUROSCI.09-10-03400.1989.","Bechara A","J Neurosci","1989","1989/10/01","PMC6569914","","10.1523/JNEUROSCI.09-10-03400.1989"
"2779356","Taste aversion involving central opioid antagonism is potentiated in morphine-dependent rats","Mucha RF.","Life Sci. 1989;45(8):671-8. doi: 10.1016/0024-3205(89)90084-2.","Mucha RF","Life Sci","1989","1989/01/01","","","10.1016/0024-3205(89)90084-2"
"2737720","Opioids in the systemic hemodynamic and renal responses to stress in spontaneously hypertensive rats","Kapusta DR, Jones SY, DiBona GF.","Hypertension. 1989 Jun;13(6 Pt 2):808-16. doi: 10.1161/01.hyp.13.6.808.","Kapusta DR","Hypertension","1989","1989/06/01","","","10.1161/01.hyp.13.6.808"
"2618077","Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans","Kotake AN, Kuwahara SK, Burton E, McCoy CE, Goldberg LI.","Xenobiotica. 1989 Nov;19(11):1247-54. doi: 10.3109/00498258909043176.","Kotake AN","Xenobiotica","1989","1989/11/01","","","10.3109/00498258909043176"
"2587611","Suppression of juvenile social behavior requires antagonism of central opioid systems","Jalowiec JE, Calcagnetti DJ, Fanselow MS.","Pharmacol Biochem Behav. 1989 Jul;33(3):697-700. doi: 10.1016/0091-3057(89)90409-7.","Jalowiec JE","Pharmacol Biochem Behav","1989","1989/07/01","","","10.1016/0091-3057(89)90409-7"
"2558367","Endogenous opioid peptides in the control of food intake in cats","Bado A, Rozé C, Lewin MJ, Dubrasquet M.","Peptides. 1989 Sep-Oct;10(5):967-71. doi: 10.1016/0196-9781(89)90177-0.","Bado A","Peptides","1989","1989/09/01","","","10.1016/0196-9781(89)90177-0"
"2548531","Effects of opiate antagonists and their quaternary analogues on nucleus accumbens self-stimulation","Trujillo KA, Belluzzi JD, Stein L.","Behav Brain Res. 1989 Jun 1;33(2):181-8. doi: 10.1016/s0166-4328(89)80049-x.","Trujillo KA","Behav Brain Res","1989","1989/06/01","","","10.1016/s0166-4328(89)80049-x"
"2482096","Naltrexone blocks the expression of the conditioned elevation of natural killer cell activity in BALB/c mice","Solvason HB, Hiramoto RN, Ghanta VK.","Brain Behav Immun. 1989 Sep;3(3):247-62. doi: 10.1016/0889-1591(89)90040-8.","Solvason HB","Brain Behav Immun","1989","1989/09/01","","","10.1016/0889-1591(89)90040-8"
"2161111","Central but not peripheral opiate receptor blockade prolonged pituitary-adrenal responses to stress","Odio M, Brodish A.","Pharmacol Biochem Behav. 1990 Apr;35(4):963-9. doi: 10.1016/0091-3057(90)90386-v.","Odio M","Pharmacol Biochem Behav","1990","1990/04/01","","","10.1016/0091-3057(90)90386-v"
"2154800","5-Methylated naloxone, naltrexone, oxymorphone, and their 14-O-methyl ethers","Schmidhammer H, Leander JD, Mayer-Valkanover K, Nussbaumer C, Schmidt C, Schoepp DD, Schratz A, Walla-Kugler M.","Prog Clin Biol Res. 1990;328:41-4.","Schmidhammer H","Prog Clin Biol Res","1990","1990/01/01","","",""
"1836972","Opiate antagonists inhibit feeding induced by 8-OH-DPAT: possible mediation in the nucleus accumbens","Fletcher PJ.","Brain Res. 1991 Sep 27;560(1-2):260-7. doi: 10.1016/0006-8993(91)91241-r.","Fletcher PJ","Brain Res","1991","1991/09/27","","","10.1016/0006-8993(91)91241-r"
"1687763","EEG evidence that morphine and an enkephalin analog cross the blood-brain barrier","Kastin AJ, Pearson MA, Banks WA.","Pharmacol Biochem Behav. 1991 Dec;40(4):771-4. doi: 10.1016/0091-3057(91)90084-f.","Kastin AJ","Pharmacol Biochem Behav","1991","1991/12/01","","","10.1016/0091-3057(91)90084-f"
"1652143","Role of central versus peripheral opioid receptors in analgesia induced by repeated administration of opioid antagonists","Walker MJ, Lê AD, Poulos CX, Cappell H.","Psychopharmacology (Berl). 1991;104(2):164-6. doi: 10.1007/BF02244172.","Walker MJ","Psychopharmacology (Berl)","1991","1991/01/01","","","10.1007/BF02244172"
"1362519","Effects of the opiates on the paraventricular nucleus in genetically polydipsic mice","Nagatomo I, Katafuchi T, Koizumi K.","Brain Res. 1992 Dec 11;598(1-2):23-32. doi: 10.1016/0006-8993(92)90163-4.","Nagatomo I","Brain Res","1992","1992/12/11","","","10.1016/0006-8993(92)90163-4"
"1324030","Modulation of immune status by a conditioned aversive stimulus: evidence for the involvement of endogenous opioids","Lysle DT, Luecken LJ, Maslonek KA.","Brain Behav Immun. 1992 Jun;6(2):179-88. doi: 10.1016/0889-1591(92)90017-i.","Lysle DT","Brain Behav Immun","1992","1992/06/01","","","10.1016/0889-1591(92)90017-i"
"1319586","Reduction of learned helplessness by central administration of quaternary naltrexone","Blustein JE, Whitehouse WG, Calcagnetti DJ, Troisi JR, Margules DL, Bersh PJ.","Physiol Behav. 1992 May;51(5):1075-8. doi: 10.1016/0031-9384(92)90095-j.","Blustein JE","Physiol Behav","1992","1992/05/01","","","10.1016/0031-9384(92)90095-j"
